US20030105499A1 - Rate adaptive cardiac rhythm management device using transthoracic impedance - Google Patents

Rate adaptive cardiac rhythm management device using transthoracic impedance Download PDF

Info

Publication number
US20030105499A1
US20030105499A1 US10/268,023 US26802302A US2003105499A1 US 20030105499 A1 US20030105499 A1 US 20030105499A1 US 26802302 A US26802302 A US 26802302A US 2003105499 A1 US2003105499 A1 US 2003105499A1
Authority
US
United States
Prior art keywords
signal
rate
multiple phase
stimulus
delivering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/268,023
Inventor
Jesse Hartley
Marc Cohen
Nicholas Stessman
Scott Reedstrom
Steven Check
James Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Original Assignee
Cardiac Pacemakers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc filed Critical Cardiac Pacemakers Inc
Priority to US10/268,023 priority Critical patent/US20030105499A1/en
Publication of US20030105499A1 publication Critical patent/US20030105499A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/36514Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
    • A61N1/36521Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure the parameter being derived from measurement of an electrical impedance

Definitions

  • This invention relates generally to cardiac rhythm management devices and methods and particularly, but not by way of limitation, to a rate adaptive cardiac rhythm management device using transthoracic impedance information, such as a minute ventilation signal, to control the rate at which pacing therapy is delivered to a patient's heart.
  • transthoracic impedance information such as a minute ventilation signal
  • Pacemakers and other cardiac rhythm management devices deliver cardiac therapy to a patient's heart to assist in obtaining a rhythm of heart contractions that maintains sufficient blood flow through the patient's circulatory system under a variety of conditions.
  • rate-adaptive pacemakers deliver electrical pacing pulses to stimulate contractions of the heart. The rate at which the pulses are delivered is adjusted to accommodate a metabolic need of the patient. During exercise, higher pacing rates are delivered, while lower pacing rates are delivered when the patient is at rest.
  • Pacemakers include specific control algorithms for tracking the parameter indicating metabolic need, and providing a control signal for adjusting the pacing rate accordingly. A variety of difficulties exist that complicate sensing of the parameter indicating metabolic need and controlling the pacing rate.
  • detecting blood pH encounters sensor stability problems. pH sensors may drift with age and time. Blood oxygenation saturation is measured using light emitters that complicate the lead system used to couple the pacemaker's pulse generator to the heart. Blood temperature is a poor indicator of metabolic need because of the long time lag between the onset of exercise and any detectable increase in blood temperature. ECG artifacts, such as QT interval, are difficult to detect in the presence of other myopotentials and motion artifacts. Breathing rate, also referred to as respiratory rate, is not particularly well correlated with the need for increased blood circulation. For example, it is possible for respiratory rate to increase while the patient is sleeping or talking.
  • Minute ventilation is a respiratory-related parameter that is a measure of the volume of air inhaled and exhaled during a particular period of time. Minute ventilation correlates well with the patient's metabolic need for an increased heart rate over a range of heart rates.
  • a minute ventilation signal can be obtained by measuring transthoracic (across the chest or thorax) impedance. Transthoracic impedance provides respiratory or ventilation information, including how fast and how deeply a patient is breathing.
  • a component of transthoracic impedance varies as the patient inhales and exhales. Ventilation (e.g., breathing rate, which is also referred to as “ventilation rate” or “VR”, and breathing volume, which is also referred to as “tidal volume” or “TV”) information is included in the impedance signal.
  • a minute ventilation signal also referred to as “minute volume” or “MV”) signal is derived from the impedance signal, as illustrated by Equation 1.
  • MV measures air flow rate (e.g., liters per minute)
  • TV measures volume per breath (e.g., liters per breath)
  • VR measures breathing rate (e.g., breaths per minute).
  • a larger MV signal indicates a metabolic need for an increased heart rate, and the pacing rate can be adjusted accordingly by a cardiac rhythm management device.
  • a cardiac rhythm management device For example, one approach for measuring transthoracic impedance is described in Hauck et al., U.S. Pat. No. 5,318,597 entitled “RATE ADAPTIVE CARDIAC RHYTHM MANAGEMENT DEVICE CONTROL ALGORITHM USING TRANSTHORACIC VENTILATION,” assigned to the assignee of the present application, the disclosure of which is incorporated herein by reference.
  • many problems must be overcome to provide the most effective cardiac rhythm management therapy to the patient in a device that can remain implanted in the patient for a long period of time before requiring a costly surgical explantation and replacement procedure.
  • Ventilation information included in the transthoracic impedance signal is confounded with a variety of extraneous signals that makes the ventilation information difficult to detect.
  • cardiac “stroke volume” or “stroke” signal The change in the transthoracic impedance signal due to blood volume changes resulting from heart contractions is referred to as cardiac “stroke volume” or “stroke” signal.
  • stroke volume The change in the transthoracic impedance signal due to blood volume changes resulting from heart contractions.
  • the frequencies of the heart contractions e.g., 1-3 Hz
  • the frequencies of the heart contractions are extremely close to the frequency of the patient's breathing (e.g., under 1 Hz). This complicates separation of the stroke signal and the ventilation signal.
  • the frequency of the stroke and ventilation signals changes according to the patient's activity. For example, a resting patient may have a heart rate of 60 beats per minute and a ventilation rate of 10 breaths per minute. When exercising, the same patient may have a heart rate of 120 beats per minute and a ventilation rate of 60 breaths per minute. The changing frequencies of the stroke and ventilation signals further complicates the separation of these signals.
  • Heart contractions are initiated by electrical depolarizations (e.g., a QRS complex) resulting from paced or intrinsic heart activity.
  • electrical depolarizations e.g., a QRS complex
  • Such electrical heart activity signals may be detected during the measurement of transthoracic impedance. This further diminishes the accuracy of the transthoracic impedance measurement, and increases the difficulty of obtaining accurate ventilation information.
  • a further problem with certain other minute ventilation based cardiac rhythm management devices results from the use of a relatively high amplitude current pulse (e.g., 1 milliampere) to detect transthoracic impedance.
  • a relatively high amplitude current pulse e.g. 1 milliampere
  • risks capturing the heart i.e., evoking a contraction
  • may trigger false detection of intrinsic heart activity by the pacemaker's sense amplifiers may produce a confusing or annoying artifact on electrocardiogram (ECG) traces or other diagnostic equipment.
  • ECG electrocardiogram
  • a cardiac rhythm management device that effectively manages the patient's heart rate based on an accurate indication of metabolic need.
  • Such a cardiac rhythm management device must be sufficiently robust to operate in the presence of extraneous noise signals that confound the indication of metabolic need.
  • the present invention provides, among other things, a method of determining transthoracic impedance in a cardiac rhythm management device.
  • a multiple phase stimulus is repeatedly delivered to a thorax region of a patient. More than one phase of each multiple phase stimuli is demodulated to obtain sample points of a response signal including transthoracic impedance information.
  • a response to each phase is sampled, weighted to obtain a filtering function, and combined.
  • a rate of delivering cardiac rhythm management therapy is adjusted based on ventilation information included in the transthoracic impedance information of a plurality of the sample points.
  • a noise-response function inhibits rate-adjustment if the transthoracic impedance signal is too noisy.
  • a interference avoidance function delays delivery of the multiple phase stimulus to avoid simultaneous occurrence with an interfering signal (e.g., a telemetry signal).
  • a cardiac stroke signal is attenuated to obtain ventilation information.
  • the lowpass cutoff frequency is adaptively selected to be below the heart rate by selecting between a number of discrete lowpass cutoff frequencies, each lowpass cutoff frequency corresponding to a particular range of values of the heart rate.
  • the method includes detecting peaks and valleys of the response signal. Differences between peaks and valleys of the response signal provide tidal volume data points, which are integrated for a predetermined period of time to obtain minute ventilation data points. A rate of delivering cardiac rhythm management therapy is adjusted based on the minute ventilation data points. Alternatively, breath-by-breath minute ventilation data points are obtained. Instead of performing the integration, time differences between the peaks and valleys of the response signal provide respiration period data points corresponding to the tidal volume data points. The tidal volume data points are divided by the corresponding respiration period data points to obtain minute ventilation data points, upon which a rate of delivering cardiac rhythm management therapy is adjusted.
  • the device includes an exciter, adapted to be coupled to a thorax of a patient for repeatedly delivering a multiphase stimulus thereto.
  • a signal processor includes a receiver for obtaining transthoracic impedance information responsive to the stimuli.
  • a demodulator included in the signal processor, includes sampling elements for demodulating the transthoracic impedance in response to different phases of the multiphase stimulus.
  • a therapy circuit is adapted to be coupled to a heart of the patient for delivering cardiac rhythm management therapy thereto.
  • a controller is coupled to the therapy circuit for adjusting a rate of delivery of the cardiac rhythm management therapy based on the transthoracic impedance.
  • the device includes a noise-reversion circuit that inhibits rate-adjustment if the transthoracic impedance signal is too noisy.
  • the device is included within a cardiac rhythm management system that also includes an endocardial lead, carrying first and second electrodes, and a housing including third and fourth electrodes.
  • a cardiac rhythm management device that includes an exciter for delivering stimuli to a thorax.
  • a signal processor includes a receiver for obtaining a transthoracic impedance responsive to the stimuli.
  • the signal processor extracts ventilation information from the transthoracic impedance.
  • the signal processor includes an adaptive lowpass filter for removing a cardiac stroke component of the transthoracic impedance signal.
  • a cutoff frequency of the adaptive lowpass filter is adaptively based on a heart rate signal of the patient. The cutoff frequency of the adaptive lowpass filter is independent of a breathing rate signal from the patient.
  • a therapy circuit is adapted to be coupled to a heart of the patient for delivering cardiac rhythm management therapy thereto.
  • a controller is coupled to the therapy circuit for adjusting a rate of delivery of the cardiac rhythm management therapy based on the ventilation information.
  • the present invention provides, among other things, a cardiac rhythm management system, device, and methods that sense transthoracic impedance and adjust a delivery rate of the cardiac rhythm management therapy based on information extracted from the transthoracic impedance.
  • the present invention effectively manages the patient's heart rate based on an accurate indication of metabolic need. It provides robust operation in the presence of extraneous noise signals that confound the indication of metabolic need. It also provides low power consumption, increasing the usable life of the battery-powered implantable device.
  • FIG. 1 is a schematic/block diagram illustrating generally one embodiment of a cardiac rhythm management system according to the present invention, including a cardiac rhythm management device and electrode connections.
  • FIG. 2 is a schematic/block diagram illustrating generally one embodiment of particular circuits included within an exciter for delivering electrical excitation stimuli to a heart.
  • FIG. 3 illustrates generally a current waveform resulting from operation of an exciter according to one aspect of the present invention.
  • FIG. 4 is a block diagram illustrating generally one embodiment of portions of a signal processor.
  • FIG. 5 is a schematic diagram illustrating generally one embodiment of a preamplifier.
  • FIG. 6 is a schematic diagram illustrating generally one embodiment of a demodulator.
  • FIG. 7 is a signal flow diagram illustrating generally one embodiment of an adaptive filter.
  • FIG. 8 is a flow chart illustrating generally one example of a sequence of steps for calculating a minute ventilation indicated rate.
  • FIG. 9 is a flow chart illustrating generally a second example of a sequence of steps for calculating a minute ventilation indicated rate.
  • FIG. 10 is a block diagram illustrating generally an alternate embodiment of a signal processor.
  • FIG. 1 is a schematic/block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of a cardiac rhythm management system 100 according to the present invention.
  • System 100 includes, among other things, cardiac rhythm management device 105 and leadwire (“lead”) 110 for communicating signals between device 105 and a portion of a living organism, such as heart 115 .
  • Embodiments of device 105 include bradycardia and antitachycardia pacemakers, cardioverters, defibrillators, combination pacemaker/defibrillators, drug delivery devices, and any other cardiac rhythm management apparatus capable of providing therapy to heart 115 .
  • System 100 may also include additional components such as, for example, a remote programmer capable of communicating with device 105 .
  • system 100 is implantable in the living organism, such as in a pectoral or abdominal region of a human patient, or elsewhere.
  • portions of system 100 e.g., device 105
  • portions of lead 110 are alternatively disposed externally to the human patient.
  • portions of lead 110 are disposed in the right ventricle, however, any other positioning of lead 110 is included within the present invention.
  • lead 110 may alternatively be positioned in the atrium or elsewhere.
  • lead 110 is a commercially available bipolar pacing lead.
  • System 100 can also include other leads in addition to lead 110 , appropriately disposed, such as in or around heart 115 , or elsewhere.
  • system 100 includes at least four electrodes, such as described in Hauck et al. U.S. Pat. No. 5,284,136 entitled “DUAL INDIFFERENT ELECTRODE PACEMAKER,” assigned to the assignee of the present invention, the disclosure of which is incorporated herein by reference. It is understood, however, that the present invention also includes using a different number of electrodes (e.g., 2 or 3 electrodes, or more than 4 electrodes).
  • a first conductor of multiconductor lead 110 electrically couples a first electrode, such as tip electrode 120 (e.g., disposed at the apex of the right ventricle of heart 115 ), to device 105 .
  • a second conductor of multiconductor lead 110 independently electrically couples a second electrode, such as ring electrode 125 , to device 105 .
  • device 105 includes a hermetically sealed housing 130 , formed from a conductive metal, such as titanium. Housing 130 (also referred to as a “case” or “can”) is substantially covered over its entire surface by a suitable insulator, such as silicone rubber, except for at a window that forms a third electrode, referred to as a “case” or “can” electrode 135 .
  • a header 140 is mounted on housing 130 for receiving lead 110 . Header 140 is formed of an insulative material, such as molded plastic. Header 140 also includes at least one receptacle, such as for receiving lead 110 and electrically coupling conductors of lead 110 to device 105 . Header 140 also includes a fourth electrode, referred to as indifferent electrode 145 .
  • FIG. 1 also illustrates generally portions of device 105 , together with schematic illustrations of connections to the various electrodes.
  • Device 105 includes an electrical stimulation source, such as exciter 150 .
  • Exciter 150 delivers an electrical excitation signal, such as a strobed sequence of current pulses or other measurement stimuli, to heart 115 (e.g., between ring electrode 125 and tip electrode 120 , or using any other electrode configuration suitable for delivering the current pulses).
  • an electrical excitation signal such as a strobed sequence of current pulses or other measurement stimuli
  • heart 115 e.g., between ring electrode 125 and tip electrode 120 , or using any other electrode configuration suitable for delivering the current pulses.
  • signal processor 155 e.g., between tip electrode 120 and indifferent electrode 145 , or any other suitable electrode configuration.
  • the response signal sensed by signal processor 155 is a voltage that represents a transthoracic (i.e., across a portion of the chest or thorax) impedance.
  • a minute ventilation signal also referred to as “minute volume” or “MV”
  • MV minute volume
  • signal processor 155 extracts ventilation information, including the MV signal, from the impedance signal. Based on the MV signal, signal processor 155 outputs an indicated rate signal at node 160 to controller 165 .
  • controller 165 Based on the indicated rate signal at node 160 , controller 165 adjusts the rate of delivery of cardiac rhythm management therapy, such as electrical pacing stimuli, to heart 115 by therapy circuit 170 .
  • cardiac rhythm management therapy such as electrical pacing stimuli
  • Such pacing stimuli includes, for example, providing bipolar pacing between tip electrode 120 and ring electrode 125 , providing unipolar pacing between can electrode 135 and either of tip electrode 120 or ring electrode 125 , or providing pacing stimuli using any other suitable electrode configuration.
  • FIG. 2 is a schematic/block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of particular circuits included within exciter 150 for delivering electrical stimuli (e.g., strobed alternating-direction constant-amplitude current pulses) to heart 115 .
  • Exciter 150 includes, among other things, bridge switcher 200 , comprising switches 200 A, 200 B, 200 C, and 200 D.
  • switches 200 A-D are implemented as transistors, such as p-channel metal-oxide semiconductor (PMOS) field-effect transistors (FETs), or any other suitable switches.
  • PMOS metal-oxide semiconductor
  • FETs field-effect transistors
  • Exciter 150 also includes current source 205 and current sink 210 .
  • each of current source 205 and current sink 210 include transistors in a regulated cascode or other suitable configuration.
  • switcher 200 is electrically coupled to case electrode 135 and ring electrode 125 through respective dc blocking capacitors 215 A and 215 B and respective switches 220 A and 220 B (e.g., PMOS transistors).
  • Switches 225 A and 225 B (e.g., PMOS transistors) precharge respective capacitors 215 A and 215 B.
  • Exciter 150 also includes a clock circuit 230 receiving one or more clock or other control signals from controller 165 and providing signals to the control terminals of each of switches 200 A-D, 220 A-B, and 225 A-B.
  • FIG. 3 illustrates generally a current waveform 300 between case electrode 135 and ring electrode 125 resulting from operation of exciter 150 according to one aspect of the present invention.
  • waveform 300 includes a multiple phase (“multiphase”) stimulus.
  • the multiphase stimulus includes a square wave, such as four current pulses 301 , 302 , 303 , and 304 in sequentially alternating polarity/direction, each current pulse being a phase of the multiphase stimulus.
  • each one of current pulses 301 - 304 has a duration that is selected at approximately between 1 and 100 microseconds (e.g., approximately between 2 and 60 microseconds, such as at 20 microseconds), to allow adequate sampling of the transthoracic impedance signal obtained in response thereto.
  • pulses 301 - 304 form a square wave having a carrier frequency of approximately 25 kilohertz.
  • Other suitable durations of current pulses 301 - 304 could also be used, providing a different resulting carrier frequency.
  • the sequence of current pulses 301 - 304 is strobed.
  • the four pulse sequence 301 - 304 is repeated at a strobing frequency (also referred to as a repetition frequency or a sampling frequency) of approximately 20 Hertz (i.e., a 50 millisecond time interval).
  • a strobing frequency also referred to as a repetition frequency or a sampling frequency
  • Other suitable strobing/repetition frequencies could also be used.
  • any strobing/repetition time interval shorter than 55 milliseconds could be used.
  • the amplitude of current pulses 301 - 304 was selected at less than approximately 1 milliampere. For example, approximately 320 microampere amplitude current pulses 301 - 304 provide an adequate excitation signal to obtain the desired response signal, while minimizing current drain of the implanted device 105 , thereby increasing its implanted longevity. However, other amplitudes of current pulses 301 - 304 could also be used. Such amplitudes of current pulses 301 - 304 should be less than the tissue stimulation threshold of the heart to avoid any resulting cardiac depolarization.
  • the strobing frequency is sufficiently fast to provide adequate sampling of ventilation or other information carried by the transthoracic impedance signal obtained in response to the electrical stimuli provided by exciter 150 .
  • ventilation information can appear at frequencies as high as approximately 1 Hertz, depending on the patient's breathing rate.
  • the strobing frequency also minimizes aliasing of a “stroke volume” component of the transthoracic impedance signal (i.e., a portion of the transthoracic impedance signal that varies along with the patient's heartbeat instead of the patient's breathing rate).
  • the stroke volume component of the transthoracic impedance signal can have frequencies as high as approximately 3 Hertz, depending on the patient's heart rate.
  • dc blocking capacitors 215 A-B Prior to each sequence of current pulses 301 - 304 , dc blocking capacitors 215 A-B are precharged by a bias circuit, such as by turning on switches 200 A-D and 225 A-B, with switches 220 A-B being off.
  • Current source 205 and current sink 210 establish the operating point of a terminal of each of dc blocking capacitors 215 A-B that is coupled to switcher 200 .
  • switches 225 A-B are turned off.
  • pulse 301 is produced by turning on switches 200 A, 200 D, and 220 A-B, such that current delivered by current source 205 leaves case electrode 135 .
  • the current returns through ring electrode 125 , and is sunk by current sink 210 .
  • pulse 302 is produced by turning on switches 200 B-C and 220 A-B, such that current delivered by current source 205 leaves ring electrode 125 .
  • the current returns through case electrode 135 , and is sunk by current sink 210 .
  • pulse 303 is produced by again turning on switches 200 A, 200 D, and 220 A-B, such that current delivered by current source 205 leaves case electrode 135 .
  • the current returns through ring electrode 125 , and is sunk by current sink 210 .
  • pulse 304 is produced by again turning on switches 200 B-C and 220 A-B, such that current delivered by current source 205 leaves ring electrode 125 .
  • the current returns through case electrode 135 , and is sunk by current sink 210 .
  • Switches 220 A-B, 200 A-D, and 225 A-B are turned off until precharging for another four current pulse sequence 301 - 304 , which is delivered approximately 50 milliseconds later, as illustrated in FIG. 3.
  • clock circuit 230 provides nonoverlapping control signals to switches 225 A-B and switches 220 A-B. As a result, switches 225 A-B are not turned on at the same time as switches 220 A-B. This avoids any coupling of either of case electrode 135 and ring electrode 125 to the positive power supply voltage V DD .
  • Waveform 300 provides several important advantages allowing efficient and accurate sensing of the MV signal, allowing system 100 to provide more effective delivery of rate-responsive cardiac rhythm management therapy to the patient.
  • system 100 allows the use of relatively low amplitude current pulses (e.g., +/ ⁇ 320 microamperes). This conserves power, allowing battery-powered portions of system 100 (e.g., device 105 ) to remain implanted in the patient for a longer usable lifetime. Because of their low amplitude, current pulses 301 - 304 do not produce any discernable artifacts on electrocardiogram (ECG) traces or on other diagnostic equipment. Such artifacts can confuse diagnosing physicians.
  • ECG electrocardiogram
  • the low amplitude current pulses 301 - 304 are also less likely to trigger false detection of intrinsic heart activity, such as by sense amplifiers included in device 105 . False detection of intrinsic heart activity can inhibit proper delivery of pacing therapy, rendering cardiac rhythm management ineffective and increasing risk to the patient. According to one aspect of the present invention, the sensitivity setting of such sense amplifiers can be increased without being affected by interference from the current pulses 301 - 304 produced by exciter 150 .
  • the low amplitude current pulses 301 - 304 avoid the risk of capturing heart 115 (i.e., inducing an electrical depolarization and heart contraction), particularly when current pulses 301 - 304 are delivered from small electrodes that are also used for delivering pacing therapy to heart 115 .
  • waveform 300 includes current pulses 301 - 304 that are strobed at a frequency of approximately 20 Hertz.
  • the 25 kilohertz carrier frequency is only present for a short fraction of the 50 millisecond strobing time interval (i.e., duty cycle of less than 1%).
  • the strobing also reduces power consumption and obtains increased implanted longevity of device 105 , as described above.
  • Waveform 300 also provides balance in both amplitude and duration for each polarity/direction of the current pulses 301 - 304 , thereby balancing the charge delivered to heart 115 .
  • Each +320 microampere pulse e.g., 301 and 303
  • an equal duration corresponding ⁇ 320 microampere pulse e.g., 302 and 304 .
  • device 105 avoids delivering the multiphase stimulus in the presence of other interfering signals, such as telemetry signals, that increase the difficulty of accurately detecting a response.
  • device 105 includes a telemetry transceiver 185 for communicating via telemetry signals (e.g., telemetry pulses) with an external programmer 190 , such as by inductively coupled coils in each of the device 105 and the external programmer 190 .
  • telemetry signals e.g., telemetry pulses
  • controller 165 delays delivery of the multiphase stimulus (e.g., current pulses 301 - 304 ), such as by approximately 1 millisecond. This avoids inaccuracies in the response signal to current pulses 301 - 304 that may result from the telemetry pulses or, similarly, from the presence of other interfering signals.
  • the multiphase stimulus e.g., current pulses 301 - 304
  • FIG. 4 is a block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of portions of signal processor 155 .
  • Signal processor 155 includes analog signal processing circuit 400 and digital signal processing circuit 405 .
  • Inputs of a preamplifier 410 (also referred to as a preamp or a receiver) of analog signal processing circuit 400 are electrically coupled to each of indifferent electrode 145 and tip electrode 120 for receiving a signal in response to the above-described stimuli provided by exciter 150 .
  • Analog signal processing circuit 400 also includes demodulator 415 , receiving the output of preamplifier 410 , and providing an output signal to bandpass filter 420 .
  • An output signal from bandpass filter 420 is received by analog-to-digital (AID) converter 425 .
  • An output signal from A/D converter 425 is received at highpass filter 430 of digital signal processing circuit 405 .
  • AID analog-to-digital
  • digital signal processing circuit 405 is included within controller 165 such as, for example, as a sequence of instructions executed by a microprocessor.
  • digital signal processing circuit 405 includes separately implemented hardware portions dedicated to performing the digital signal processing tasks described below.
  • An output signal from highpass filter 430 is received by adaptive lowpass filter 435 of digital signal processing circuit 405 .
  • Minute ventilation calculation module 440 receives an output signal from adaptive lowpass filter 435 , and provides a resulting indicated rate signal at node 160 to controller 165 .
  • FIG. 5 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of preamplifier 410 .
  • Preamplifier 410 includes a switched-capacitor (SC) differential amplifier 500 .
  • Preamplifier 410 is electrically coupled to indifferent electrode 145 and tip electrode 120 through respective switches 510 and 515 and respective resistors 520 and 525 .
  • Switches 510 and 515 are turned on only during the approximate time when the stimuli current pulses 301 - 304 are being delivered by exciter 150 .
  • Resistors 520 and 525 provide antialiasing/bandlimiting of the input signals received from indifferent electrode 145 and tip electrode 120 .
  • Differential amplifier 500 includes input capacitors 530 and 535 , coupled to resistors 520 and 525 respectively, and also coupled to a respective positive input at node 540 and a negative input, at node 545 , of a differential-input/differential-output operational amplifier 550 .
  • Feedback capacitors 560 and 565 are coupled from a respective negative output, at node 570 , and a positive output, at node 575 , of operational amplifier 550 , to its respective positive input, at node 540 , and negative input, at node 545 .
  • input capacitors 530 and 535 have approximately 10 times the capacitance value of respective feedback capacitors 560 and 565 .
  • Differential amplifier 500 also includes autozeroing input switches, 580 and 585 , coupling respective input nodes 540 and 545 to respective reference voltages (e.g., a ground voltage).
  • Autozeroing output switches 590 and 595 couple respective output nodes 570 and 575 to respective reference voltages (e.g., a ground voltage).
  • Switches 580 , 585 , 590 , and 595 provide zeroing of corresponding feedback capacitors 560 and 565 .
  • Switches 580 and 585 further establish the bias points of the input nodes 540 and 545 of operational amplifier 550 , such as during sampling of signals from indifferent electrode 145 and tip electrode 120 onto input capacitors 530 and 535 .
  • Preamplifier 410 receives a voltage based on the transthoracic impedance between indifferent electrode 145 and tip electrode 120 .
  • a transthoracic impedance of 50 ohms results in a voltage between the inputs of differential amplifier 500 of approximately 16 millivolts.
  • the transthoracic impedance varies as the patient breathes, increasing as air fills the patient's thoracic cavity during inspiration and decreasing as air is released during expiration.
  • the transthoracic impedance may vary, for example, by approximately 2 ohms during respiration, resulting in an approximately 0.64 millivolt modulation of the approximately 16 millivolt baseline signal appearing between the inputs of differential amplifier 500 .
  • These impedance and voltage values are recited by way of example only; actual impedance and voltage values will vary according to, among other things, differences in patient anatomy and electrode placement.
  • the electrodes used for delivering the excitation current are different from the electrodes used for sensing the response thereto (e.g., indifferent electrode 145 and tip electrode 120 ).
  • the same electrodes could be used for delivering the excitation current and sensing the response thereto.
  • differential amplifier 500 provides an effective voltage gain of approximately 6.
  • the 16 millivolt baseline signal is amplified to approximately 100 millivolts by differential amplifier 500 and the resulting signal is provided to demodulator 415 .
  • Demodulator 415 samples the signal obtained in response to current pulses 301 - 304 after the above-described amplification by preamplifier 410 .
  • the output of preamplifier 410 is sampled at the end of each of current pulses 301 - 304 .
  • Demodulator 415 combines these four samples into a single value using a weighted average. The resulting weighted average represents the total impedance (i.e., including both baseline and ventilation components) obtained for the sequence of four current pulses 301 - 304 .
  • the weighted average is formed by weighting the second and third samples, obtained from respective current pulses 302 and 303 , by a factor of approximately 3.0 relative to the first and fourth samples, obtained from respective current pulses 301 and 304 .
  • Weighting the samples advantageously provides an additional highpass filtering function, substantially transmitting the transthoracic impedance signal at the 25 kilohertz carrier frequency of the current pulses 301 - 304 , while substantially rejecting out-of-band signals.
  • demodulator 415 provides additional rejection of low-frequency signals, such as R-waves and other electrical signals produced by heart 115 .
  • a transfer function provided by one embodiment of demodulator 415 is described in the z-domain, as illustrated in Equation 2.
  • demodulator 415 provides a voltage gain that is approximately between 1.75 and 2.0 for the in-band transthoracic impedance signal. Moreover, demodulator 415 also advantageously attenuates signals at frequencies below 100 Hz by a factor of at least approximately 120 dB, including such signals as R-waves and other electrical intrinsic heart activity signals produced by heart 115 , which can interfere with sensing the patient's transthoracic impedance.
  • FIG. 6 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of a switched-capacitor demodulator 415 .
  • the output signal from preamplifier 410 is sampled onto capacitors 600 A-B in response to current pulse 301 , onto capacitors 605 A-B in response to current pulse 302 , onto capacitors 610 A-B in response to current pulse 303 , and onto capacitors 615 A-B in response to current pulse 304 .
  • Capacitors 605 A-B and 610 A-B provide 3 times the capacitance value of capacitors 600 A-B and 615 A-B, in order to provide the above-described weighting of the samples.
  • switched-capacitor integrator 620 also referred to as a summer.
  • dummy capacitors 625 A-B are dummy capacitors 625 A-B.
  • Each of dummy capacitors 625 A-B has a capacitance value that is twice that of one of capacitors 600 A-B, and twice that of one of capacitors 615 A-B.
  • Dummy capacitors 625 A-B are switched in during sample of current pulses 301 and 304 .
  • demodulator 415 presents the same load capacitance to preamplifier 410 during sampling of each of the four current pulses 301 - 304 . As seen in FIG.
  • the charge that is sampled onto dummy capacitors 625 A-B is not included in the weighted sample (i.e., the resulting charge is not included in the integration provided by integrator 620 ).
  • the capacitors illustrated in FIG. 6 are initialized (e.g., discharged) prior to sampling any particular sequence of current pulses 301 - 304 .
  • integrator 620 includes input capacitors 650 and 655 , which are autozeroed by switches, as illustrated, during the clock phase ⁇ AZ .
  • An integration capacitor 660 which is in the feedback path around operational amplifier 665 , sums the weighted samples obtained in response to the four current pulses 301 - 304 during an integration clock phase ⁇ I .
  • a noise sampling/integration capacitor 630 which is also in the feedback path around operational amplifier 665 , sums the weighted samples obtained in the absence of delivered current pulses during a noise integration clock phase ⁇ NI , as described below.
  • Integrator 620 also provides a matching network 670 on the other input of operational amplifier 665 for matching the above-described switched capacitor operation.
  • demodulator 415 also provides a noise sensing mode of operation. In normal operation, demodulator 415 samples the output of filter/amplifier 410 in response to current pulses 301 - 304 provided by exciter 150 . During a noise sensing mode of operation, exciter 150 is turned off (i.e., current pulses 301 - 304 are not provided), and demodulator 415 samples, onto switched-in noise sampling/integration capacitor 630 , noise arising from external sources (e.g., heart signals or any environmental noise sources) and internal noise produced by circuits coupled to the input of the demodulator 415 . In particular, demodulator 415 is capable of sensing noise that is at frequencies close to the 25 kilohertz carrier frequency of the current pulses 301 - 304 .
  • the gain of demodulator 415 is increased (e.g., by a factor of approximately 2.0-2.5) during noise sensing mode in order to provide more sensitive noise detection.
  • the noise sampling/integration capacitor 630 used during noise sensing is different in value from a corresponding integration capacitor used during normal operation of demodulator 415 , in order to provide a different gain during noise sensing.
  • device 105 also includes a noise reversion circuit based on the noise sensed by demodulator 415 when exciter 150 is turned off.
  • a noise comparator 635 receives a signal derived from the output of demodulator 415 . Comparator 635 determines whether the detected noise exceeds a particular programmable threshold value. If the detected noise exceeds the threshold value, subsequent circuits ignore the output of demodulator 415 (e.g., until the detected noise again falls below the threshold value).
  • the programmable threshold value used by comparator 635 is implemented as a programmable switched-capacitor array, providing threshold voltages ranging between approximately 4-120 millivolts at the output of demodulator 415 (corresponding to an impedance noise threshold between approximately 0.4-12 ohms).
  • bandpass filter 420 provides a passband between single pole corner frequencies at 0.1 Hz and 2.0 Hz, and includes a gain stage providing a voltage gain that is programmable (e.g., 6 ⁇ , 12 ⁇ , and 24 ⁇ ).
  • the 0.1 Hz low frequency (highpass) pole substantially attenuates the baseline component of the transthoracic impedance signal, but substantially transmits the time-varying component of the transthoracic impedance signal representing ventilation.
  • the 2.0 Hz high frequency (lowpass) pole substantially attenuates other time-varying components of the transthoracic impedance signal that do not contribute substantial ventilation information.
  • the lowpass pole effectively contributes to the attenuation of signal components due to the cardiac stroke signal resulting from the beating of heart 115 .
  • removal of the stroke signal is both difficult and particularly important for properly adapting the delivered pacing rate based on minute ventilation, since the stroke signal is very close in frequency to the desired ventilation signal.
  • the lowpass pole also filters out other noise at frequencies that exceed the lowpass pole frequency.
  • bandpass filter 420 includes a switched-capacitor biquadratic filter stage, series-coupled with a subsequent switched-capacitor gain stage. Capacitance values of the switched-capacitor gain stage are user-programmable, thereby obtaining differing voltage gains, as described above.
  • the output of the switched capacitor gain stage included in bandpass filter 420 is provided to the input of A/D converter 425 .
  • A/D converter 425 receives the output signal of bandpass filter 420 and provides a resulting digitized output signal to highpass filter 430 of digital signal processing circuit 405 .
  • A/D converter 425 is implemented as an 8-bit, successive approximation type switched-capacitor A/D converter having an input range of approximately 1 Volt.
  • A/D converter 425 provides one 8-bit digital word corresponding to each sequence of four current pulses 301 - 304 delivered by exciter 150 .
  • Many different implementations of A/D converter 425 will be suitable for use in the present invention. For example, a different A/D converter resolution (greater than or less than 8 bits) may be used.
  • Highpass filter 430 includes, in one embodiment, a single-pole infinite impulse response (IIR) digital filter that receives the 8-bit digital output signal from A/D converter 425 , removing frequency components below its highpass cutoff frequency of approximately 0.1 Hz. Many other different embodiments of highpass filter 430 will also be suitable for use in the present invention. Highpass filter 430 advantageously further attenuates baseline dc components of the transthoracic impedance and any dc offset voltages created by A/D converter 425 . The output of highpass filter 430 is provided to adaptive lowpass filter 435 .
  • IIR infinite impulse response
  • Adaptive lowpass filter 435 receives the output signal of highpass filter 430 and attenuates frequency components of the signal that exceed the lowpass cutoff frequency of adaptive lowpass filter 435 . Attenuated frequencies include the cardiac stroke signal, resulting from changes in blood volume in heart 115 as it contracts during each cardiac cycle, which appears as a component of the transthoracic impedance signal. Thus, the cardiac stroke signal confounds the desired ventilation information indicating the metabolic need for adjusting pacing rate.
  • the component of the transthoracic impedance due to the stroke signal can be substantial.
  • attenuation of the stroke signal is particularly important for properly adapting the delivered pacing rate based on minute ventilation.
  • the stroke signal is difficult to attenuate, since it is very close in frequency to the desired ventilation signal.
  • the frequencies of each of the stroke and ventilation signals varies according to the patient's activity, making the stroke and ventilation signals difficult to separate.
  • Adaptive lowpass filter 435 provides effective attenuation of the stroke component of the processed transthoracic impedance signal received from highpass filter 430 .
  • Frequency components above a lowpass cutoff frequency are attenuated.
  • the frequency components above the lowpass cutoff frequency are attenuated by at least 30 decibels while preserving ventilation information having frequency components below the lowpass cutoff frequency.
  • the lowpass cutoff frequency is adaptively based on a heart rate of the patient and, according to a further aspect of the invention, is independent of any breathing rate signal obtained from the patient.
  • the patient's heart rate is detected by sense amplifiers 175 , and provided to adaptive lowpass filter 435 , such as by controller 165 , for adjusting the lowpass cutoff frequency of adaptive lowpass filter 435 accordingly.
  • Table 1 illustrates, by way of example, but not by way of limitation, one mapping of different lowpass cutoff frequencies of adaptive lowpass filter 435 to ranges of the patient's heart rate. Other mappings may also be used.
  • TABLE 1 Exemplary lowpass cutoff frequencies of adaptive lowpass filter 435 based on different sensed heart rates.
  • Heart Rate beats per minute
  • Lowpass cutoff frequency ⁇ 68 0.5 Hz 68-88 0.75 Hz >88 1.0 Hz
  • a 0.5 Hz cutoff frequency is used when the sensed heart rate is less than 68 beats per minute.
  • adaptive lowpass filter 435 switches its lowpass cutoff frequency to 0.75 Hz.
  • adaptive lowpass filter 435 switches its lowpass cutoff frequency to 1.0 Hz.
  • adaptive lowpass filter 435 adjusts the lowpass cutoff frequency according to Table 1.
  • the present invention bases adaptive adjustment of the lowpass cutoff frequency only on heart rate. Among other things, this reduces computational complexity and power consumption associated with monitoring the breathing rate for adjusting the lowpass cutoff frequency. This also ensures that adaptive lowpass filter 435 removes the stroke signal for all particular combinations of respiration rate and heart rate, so that pacing rate is appropriately adjusted based on minute ventilation.
  • adaptive filter 435 uses a 4-pole Chebyshev filter that is better suited to data represented by fewer bits (e.g., 8-bit fixed point arithmetic). This conserves power and avoids instability and other potential problems of quantization.
  • adaptive lowpass filter 435 uses a state-space structure, rather than in a conventional direct form structure. The state-space structure further reduces the effects of coefficient quantization and roundoff noise.
  • One example of such a state-space structure is described in Leland B. Jackson, “Digital Filters and Signal Processing,” 2nd ed., pp. 332-340, Kluwer Academic Publishers, Boston, Mass., the disclosure of which is incorporated herein by reference.
  • FIG. 7 is a signal flow diagram illustrating generally one embodiment of adaptive filter 435 having a state-space topology.
  • FIG. 7 includes scaling elements, delay elements, and summation elements. Signals output from summation elements are also scaled, as illustrated in FIG. 7. As with any DSP filter, saturation of signals at particular nodes should be avoided by adjusting the coefficients according to conventional DSP coefficient scaling techniques.
  • One embodiment of hexadecimal values of filter coefficients is illustrated by way of example, but not by way of limitation, in Table 2.
  • Adaptive lowpass filter 435 outputs a signal based on transthoracic impedance and carrying ventilation information.
  • the stroke component of the transthoracic impedance signal is substantially removed.
  • the output of adaptive lowpass filter 435 is provided to MV calculation module 440 , which calculates a minute ventilation indicated pacing rate based on the ventilation information.
  • MV calculation module 440 is implemented as a sequence of instructions executed on any suitable microprocessor, such as a Zilog Z80-type microprocessor.
  • MV calculation module 440 is implemented as any other hardware or software configuration capable of calculating an indicated pacing rate based on ventilation information.
  • a sequence of instructions executed on a microprocessor for calculating a minute ventilation indicated rate is described below, and illustrated in the flow chart of FIG. 8.
  • MV calculation module 440 receives from adaptive lowpass filter 435 a digital signal representing a time-varying transthoracic impedance.
  • the impedance signal is centered around zero, with positive values representing inhalation, and negative values representing exhalation.
  • the maximum (most positive) and minimum (most negative) values of the impedance signal are stored in separate storage registers. After each breath, an interrupt is provided to the microprocessor, such as upon each positive-going zero-crossing.
  • the tidal volume (TV) is calculated upon receiving the interrupt.
  • the tidal volume is obtained by reading the storage registers, and taking the difference between the maximum and minimum values of the impedance signal held for the patient's previous breath. A larger tidal volume indicates a deeper breath than a smaller tidal volume.
  • a tidal volume data point is produced at step 805 for each breath by the patient.
  • the tidal volume is integrated (i.e., the tidal volume data points are summed) for a predetermined period of time (e.g., approximately 8 seconds), obtaining a minute ventilation data point, as described in Equation 1. After each 8 second integration period, the minute ventilation data point is output, and a new integration (i.e., summation) of tidal volume commences.
  • Steps 815 and 820 include carrying out concurrent moving short term and long term averages, respectively.
  • the short term average (“STA,” also referred to as a “boxcar” average) at step 815 represents, at a particular point in time, a moving average of the minute ventilation data points over the previous approximately 32 seconds.
  • the short term average represents the present minute ventilation indication of metabolic need.
  • the long term average (“LTA”) at step 820 represents, at a particular point in time, a moving average of the minute ventilation data points over the previous approximately 2 hours.
  • the long term average approximates the resting state of the minute ventilation indicator.
  • the long term average at step 820 is carried out by an IIR digital filter.
  • the short term and long term averages are compared. In one embodiment, this comparison involves subtracting the long term average from the short term average. The difference is optionally scaled, and used to adjust the pacing rate when the short term average exceeds the long term average. In one embodiment, the rate is adjusted according to Equation 3.
  • Equation 3 STA represents the short term average, LTA represents the long term average, K represents an optional scaling coefficient, LRL is a programmable lower rate limit to which the incremental sensor driven rate is added, and RATE MV is the minute ventilation indicated rate at which pacing therapy is delivered.
  • RATE MV is a linear function of the difference STA-LTA. Also, in this embodiment, if the value of the short term average is less than the value of the long term average, pacing therapy is delivered at the lower rate limit (LRL).
  • more than one scaling coefficient K is used, obtaining a piecewise linear mapping of minute ventilation to the resulting minute ventilation indicated rate. For example, when the STA-LTA difference exceeds a certain threshold value, a smaller scaling coefficient K is used. This reduces the incremental increase in pacing rate for high pacing rates, when compared to the incremental increase in pacing rate for pacing rates close to the lower rate limit (LRL).
  • LNL lower rate limit
  • Step 825 is alternatively implemented as a ratio STA/LTA, rather than the difference STA-LTA.
  • the rate is adjusted according to Equation 4 when STA exceeds LTA.
  • RATE MV LRL + C ⁇ ( STA LTA ) ( 4 )
  • Equation 4 STA represents the short term average, LTA represents the long term average, C represents an optional scaling coefficient, LRL is a programmable lower rate limit to which the incremental sensor driven rate is added, and RATE MV is the minute ventilation indicated rate at which pacing therapy is delivered. If the value of the short term average is less than the value of the long term average, pacing therapy is delivered at the lower rate limit (LRL). In this embodiment, reduced incremental rate at high pacing rates is obtained by using more than one scaling coefficient, as described above.
  • rate modifiers can also be used to obtain a minute ventilation indicated rate.
  • the minute ventilation indicated rate can be combined, blended, or otherwise used in conjunction with other rate indicators, such as those derived from different sensors providing different indicators of metabolic need (e.g., acceleration).
  • Such indicators may have different response characteristics (e.g., time lag after onset of exercise) that are advantageously combined with the minute ventilation rate indication described above.
  • the indicated rate (e.g., RATE MV ) is provided to controller 165 , for adjusting the rate of pacing therapy delivered by therapy circuit 170 .
  • FIG. 9 is a flow chart, similar to that of FIG. 8, illustrating generally another embodiment of the invention that uses a breath-by-breath minute ventilation calculation.
  • time differences corresponding to the peaks and valleys of the response signal are used to obtain respiration period data points corresponding to the tidal volume data points obtained in step 805 .
  • a breath-by-breath indication of minute ventilation is obtained, such as by dividing the tidal volume data points by the corresponding respiration period data points to obtain minute ventilation data points.
  • the rate of delivering cardiac rhythm management therapy is then adjusted based on the minute ventilation data points, as described above with respect to FIG. 8.
  • FIG. 10 is a block diagram illustrating generally one such variation on signal processor 155 .
  • the bandpass filter 420 of FIG. 4 is implemented digitally in the signal processor 155 of FIG. 10.
  • Other variations are also possible without departing from the present invention.
  • the above description illustrates, by way of example, but not by way of limitation, a particular embodiment of the present invention in which ventilation information is extracted from a detected transthoracic impedance, and the rate of delivery of cardiac rhythm management therapy is adjusted based on an indicator derived from the ventilation information.
  • the present invention also includes the extraction of other information (e.g., cardiac stroke information) from the transthoracic impedance, such as for adjusting the rate of delivery of cardiac rhythm management therapy based on an indicator extracted from such information.
  • other information e.g., cardiac stroke information
  • the present invention provides, among other things, a cardiac rhythm management device that senses transthoracic impedance and adjusts a delivery rate of the cardiac rhythm management therapy based on information extracted from the transthoracic impedance.
  • an adaptive lowpass filter removes the stroke signal from the transthoracic impedance signal while preserving the ventilation information.
  • the adaptive filter includes a lowpass cutoff frequency that is adaptively based on the patient's heart rate, but independent of a breathing rate signal.
  • a weighted demodulation provides filtering that enhances rejection of unwanted signals.
  • Minute ventilation is obtained from tidal volume obtained from the ventilation information.
  • An indicated rate is based on a difference between, or ratio of, short and long term averages of the minute ventilation information, unless noise exceeding a threshold is detected.
  • the present invention effectively manages the patient's heart rate based on an accurate indication of metabolic need. It provides robust operation in the presence of extraneous noise signals that confound the indication of metabolic need. It also provides low power consumption, increasing the usable life of the battery-powered implantable device.

Abstract

A cardiac rhythm management (CRM) device detects transthoracic impedance, extracts ventilation or other information, and adjusts a delivery rate of the CRM therapy accordingly. A four-phase sequence of alternating direction current pulse stimuli is periodically delivered to a patient's thorax. A transthoracic impedance signal is extracted using a weighted demodulation. Signal processing extracts ventilation information and removes cardiac stroke information using an adaptive lowpass filter. The adaptive filter cutoff frequency is based on the patient's heart rate; a higher cutoff frequency is provided for higher heart rates. Peak/valley detection indicates tidal volume, which is integrated to extract minute ventilation (MV). Short and long term averages are formed and compared to establish a MV indicated rate. Rate adjustment ignores MV information when a noise-measurement exceeds a threshold. An interference avoidance circuit delays delivery of the stimuli when telemetry pulses or other interfering signals are detected.

Description

    CROSS-REFERENCE TO RELATED APPLICATION(s)
  • This patent application is a continuation of U.S. patent application Ser. No. 09/492,912, filed on Jan. 20, 2000, which is a continuation of U.S. patent application Ser. No. 09/032,731, filed on Feb. 27, 1998, now issued as U.S. Pat. No. 6,076,015, the specifications of which are incorporated by reference herein.[0001]
  • TECHNICAL FIELD OF THE INVENTION
  • This invention relates generally to cardiac rhythm management devices and methods and particularly, but not by way of limitation, to a rate adaptive cardiac rhythm management device using transthoracic impedance information, such as a minute ventilation signal, to control the rate at which pacing therapy is delivered to a patient's heart. [0002]
  • BACKGROUND OF THE INVENTION
  • Pacemakers and other cardiac rhythm management devices deliver cardiac therapy to a patient's heart to assist in obtaining a rhythm of heart contractions that maintains sufficient blood flow through the patient's circulatory system under a variety of conditions. In particular, rate-adaptive pacemakers deliver electrical pacing pulses to stimulate contractions of the heart. The rate at which the pulses are delivered is adjusted to accommodate a metabolic need of the patient. During exercise, higher pacing rates are delivered, while lower pacing rates are delivered when the patient is at rest. [0003]
  • Different parameters are used as an indication of the patient's metabolic need for pacing therapy, including: blood pH, blood temperature, electrocardiogram (ECG) artifacts such as QT interval, blood oxygen saturation, breathing rate, minute ventilation, etc. Pacemakers include specific control algorithms for tracking the parameter indicating metabolic need, and providing a control signal for adjusting the pacing rate accordingly. A variety of difficulties exist that complicate sensing of the parameter indicating metabolic need and controlling the pacing rate. [0004]
  • For example, detecting blood pH encounters sensor stability problems. pH sensors may drift with age and time. Blood oxygenation saturation is measured using light emitters that complicate the lead system used to couple the pacemaker's pulse generator to the heart. Blood temperature is a poor indicator of metabolic need because of the long time lag between the onset of exercise and any detectable increase in blood temperature. ECG artifacts, such as QT interval, are difficult to detect in the presence of other myopotentials and motion artifacts. Breathing rate, also referred to as respiratory rate, is not particularly well correlated with the need for increased blood circulation. For example, it is possible for respiratory rate to increase while the patient is sleeping or talking. [0005]
  • Minute ventilation (also referred to as “minute volume” or “MV”) is a respiratory-related parameter that is a measure of the volume of air inhaled and exhaled during a particular period of time. Minute ventilation correlates well with the patient's metabolic need for an increased heart rate over a range of heart rates. A minute ventilation signal can be obtained by measuring transthoracic (across the chest or thorax) impedance. Transthoracic impedance provides respiratory or ventilation information, including how fast and how deeply a patient is breathing. [0006]
  • A component of transthoracic impedance varies as the patient inhales and exhales. Ventilation (e.g., breathing rate, which is also referred to as “ventilation rate” or “VR”, and breathing volume, which is also referred to as “tidal volume” or “TV”) information is included in the impedance signal. A minute ventilation signal (also referred to as “minute volume” or “MV”) signal is derived from the impedance signal, as illustrated by [0007] Equation 1. MV measures air flow rate (e.g., liters per minute), TV measures volume per breath (e.g., liters per breath), and VR measures breathing rate (e.g., breaths per minute).
  • MV=TV×VR  (1)
  • A larger MV signal indicates a metabolic need for an increased heart rate, and the pacing rate can be adjusted accordingly by a cardiac rhythm management device. For example, one approach for measuring transthoracic impedance is described in Hauck et al., U.S. Pat. No. 5,318,597 entitled “RATE ADAPTIVE CARDIAC RHYTHM MANAGEMENT DEVICE CONTROL ALGORITHM USING TRANSTHORACIC VENTILATION,” assigned to the assignee of the present application, the disclosure of which is incorporated herein by reference. However, many problems must be overcome to provide the most effective cardiac rhythm management therapy to the patient in a device that can remain implanted in the patient for a long period of time before requiring a costly surgical explantation and replacement procedure. [0008]
  • First, ventilation information included in the transthoracic impedance signal is confounded with a variety of extraneous signals that makes the ventilation information difficult to detect. For example, as the heart contracts during each cardiac cycle, its blood volume changes, contributing to a significant change in the transthoracic impedance signal that is unrelated to the ventilation information. The change in the transthoracic impedance signal due to blood volume changes resulting from heart contractions is referred to as cardiac “stroke volume” or “stroke” signal. Moreover, the frequencies of the heart contractions (e.g., 1-3 Hz) are extremely close to the frequency of the patient's breathing (e.g., under 1 Hz). This complicates separation of the stroke signal and the ventilation signal. [0009]
  • Furthermore, the frequency of the stroke and ventilation signals changes according to the patient's activity. For example, a resting patient may have a heart rate of 60 beats per minute and a ventilation rate of 10 breaths per minute. When exercising, the same patient may have a heart rate of 120 beats per minute and a ventilation rate of 60 breaths per minute. The changing frequencies of the stroke and ventilation signals further complicates the separation of these signals. [0010]
  • Another aspect of heart contractions also masks the ventilation signal. Heart contractions are initiated by electrical depolarizations (e.g., a QRS complex) resulting from paced or intrinsic heart activity. Such electrical heart activity signals may be detected during the measurement of transthoracic impedance. This further diminishes the accuracy of the transthoracic impedance measurement, and increases the difficulty of obtaining accurate ventilation information. [0011]
  • A further problem with certain other minute ventilation based cardiac rhythm management devices results from the use of a relatively high amplitude current pulse (e.g., 1 milliampere) to detect transthoracic impedance. Using high amplitude stimuli wastes power, risks capturing the heart (i.e., evoking a contraction), may trigger false detection of intrinsic heart activity by the pacemaker's sense amplifiers, and may produce a confusing or annoying artifact on electrocardiogram (ECG) traces or other diagnostic equipment. [0012]
  • Thus, there is a need for a cardiac rhythm management device that effectively manages the patient's heart rate based on an accurate indication of metabolic need. Such a cardiac rhythm management device must be sufficiently robust to operate in the presence of extraneous noise signals that confound the indication of metabolic need. There is a further need for such a device to operate at low power consumption, in order to maximize the usable life of the battery-powered implantable device. [0013]
  • SUMMARY OF THE INVENTION
  • The present invention provides, among other things, a method of determining transthoracic impedance in a cardiac rhythm management device. A multiple phase stimulus is repeatedly delivered to a thorax region of a patient. More than one phase of each multiple phase stimuli is demodulated to obtain sample points of a response signal including transthoracic impedance information. [0014]
  • In one embodiment, a response to each phase is sampled, weighted to obtain a filtering function, and combined. In another embodiment, a rate of delivering cardiac rhythm management therapy is adjusted based on ventilation information included in the transthoracic impedance information of a plurality of the sample points. In another embodiment, a noise-response function inhibits rate-adjustment if the transthoracic impedance signal is too noisy. In a further embodiment, a interference avoidance function delays delivery of the multiple phase stimulus to avoid simultaneous occurrence with an interfering signal (e.g., a telemetry signal). [0015]
  • Another aspect of the invention includes a method of determining transthoracic impedance in a cardiac rhythm management device that includes delivering stimuli to a thorax of the patient, sensing a response signal including transthoracic impedance information, attenuating a component of the response signal having frequencies above a lowpass cutoff frequency, and adaptively basing the lowpass cutoff frequency on a heart rate, and independent of a breathing rate signal, from the patient. [0016]
  • In one such embodiment, a cardiac stroke signal is attenuated to obtain ventilation information. The lowpass cutoff frequency is adaptively selected to be below the heart rate by selecting between a number of discrete lowpass cutoff frequencies, each lowpass cutoff frequency corresponding to a particular range of values of the heart rate. [0017]
  • In a further embodiment, the method includes detecting peaks and valleys of the response signal. Differences between peaks and valleys of the response signal provide tidal volume data points, which are integrated for a predetermined period of time to obtain minute ventilation data points. A rate of delivering cardiac rhythm management therapy is adjusted based on the minute ventilation data points. Alternatively, breath-by-breath minute ventilation data points are obtained. Instead of performing the integration, time differences between the peaks and valleys of the response signal provide respiration period data points corresponding to the tidal volume data points. The tidal volume data points are divided by the corresponding respiration period data points to obtain minute ventilation data points, upon which a rate of delivering cardiac rhythm management therapy is adjusted. [0018]
  • Another aspect of the present invention includes a cardiac rhythm management device. The device includes an exciter, adapted to be coupled to a thorax of a patient for repeatedly delivering a multiphase stimulus thereto. A signal processor includes a receiver for obtaining transthoracic impedance information responsive to the stimuli. A demodulator, included in the signal processor, includes sampling elements for demodulating the transthoracic impedance in response to different phases of the multiphase stimulus. A therapy circuit is adapted to be coupled to a heart of the patient for delivering cardiac rhythm management therapy thereto. A controller is coupled to the therapy circuit for adjusting a rate of delivery of the cardiac rhythm management therapy based on the transthoracic impedance. [0019]
  • In one embodiment, the device includes a noise-reversion circuit that inhibits rate-adjustment if the transthoracic impedance signal is too noisy. In a further embodiment, the device is included within a cardiac rhythm management system that also includes an endocardial lead, carrying first and second electrodes, and a housing including third and fourth electrodes. [0020]
  • Another aspect of the invention includes a cardiac rhythm management device that includes an exciter for delivering stimuli to a thorax. A signal processor includes a receiver for obtaining a transthoracic impedance responsive to the stimuli. The signal processor extracts ventilation information from the transthoracic impedance. The signal processor includes an adaptive lowpass filter for removing a cardiac stroke component of the transthoracic impedance signal. A cutoff frequency of the adaptive lowpass filter is adaptively based on a heart rate signal of the patient. The cutoff frequency of the adaptive lowpass filter is independent of a breathing rate signal from the patient. A therapy circuit is adapted to be coupled to a heart of the patient for delivering cardiac rhythm management therapy thereto. A controller is coupled to the therapy circuit for adjusting a rate of delivery of the cardiac rhythm management therapy based on the ventilation information. [0021]
  • The present invention provides, among other things, a cardiac rhythm management system, device, and methods that sense transthoracic impedance and adjust a delivery rate of the cardiac rhythm management therapy based on information extracted from the transthoracic impedance. The present invention effectively manages the patient's heart rate based on an accurate indication of metabolic need. It provides robust operation in the presence of extraneous noise signals that confound the indication of metabolic need. It also provides low power consumption, increasing the usable life of the battery-powered implantable device. Other advantages will be apparent upon reading the following detailed description of the invention, together with the accompanying drawings which form a part thereof. [0022]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the drawings, like numerals describe substantially similar components throughout the several views. [0023]
  • FIG. 1 is a schematic/block diagram illustrating generally one embodiment of a cardiac rhythm management system according to the present invention, including a cardiac rhythm management device and electrode connections. [0024]
  • FIG. 2 is a schematic/block diagram illustrating generally one embodiment of particular circuits included within an exciter for delivering electrical excitation stimuli to a heart. [0025]
  • FIG. 3 illustrates generally a current waveform resulting from operation of an exciter according to one aspect of the present invention. [0026]
  • FIG. 4 is a block diagram illustrating generally one embodiment of portions of a signal processor. [0027]
  • FIG. 5 is a schematic diagram illustrating generally one embodiment of a preamplifier. [0028]
  • FIG. 6 is a schematic diagram illustrating generally one embodiment of a demodulator. [0029]
  • FIG. 7 is a signal flow diagram illustrating generally one embodiment of an adaptive filter. [0030]
  • FIG. 8 is a flow chart illustrating generally one example of a sequence of steps for calculating a minute ventilation indicated rate. [0031]
  • FIG. 9 is a flow chart illustrating generally a second example of a sequence of steps for calculating a minute ventilation indicated rate. [0032]
  • FIG. 10 is a block diagram illustrating generally an alternate embodiment of a signal processor. [0033]
  • DETAILED DESCRIPTION OF THE INVENTION
  • In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents. [0034]
  • Electrode Configuration and Top-Level Block Diagram
  • FIG. 1 is a schematic/block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of a cardiac [0035] rhythm management system 100 according to the present invention. System 100 includes, among other things, cardiac rhythm management device 105 and leadwire (“lead”) 110 for communicating signals between device 105 and a portion of a living organism, such as heart 115. Embodiments of device 105 include bradycardia and antitachycardia pacemakers, cardioverters, defibrillators, combination pacemaker/defibrillators, drug delivery devices, and any other cardiac rhythm management apparatus capable of providing therapy to heart 115. System 100 may also include additional components such as, for example, a remote programmer capable of communicating with device 105.
  • In one embodiment, [0036] system 100 is implantable in the living organism, such as in a pectoral or abdominal region of a human patient, or elsewhere. In another embodiment, portions of system 100 (e.g., device 105) are alternatively disposed externally to the human patient. In the illustrated embodiment, portions of lead 110 are disposed in the right ventricle, however, any other positioning of lead 110 is included within the present invention. For example, lead 110 may alternatively be positioned in the atrium or elsewhere. In one embodiment, lead 110 is a commercially available bipolar pacing lead. System 100 can also include other leads in addition to lead 110, appropriately disposed, such as in or around heart 115, or elsewhere.
  • In one embodiment, [0037] system 100 includes at least four electrodes, such as described in Hauck et al. U.S. Pat. No. 5,284,136 entitled “DUAL INDIFFERENT ELECTRODE PACEMAKER,” assigned to the assignee of the present invention, the disclosure of which is incorporated herein by reference. It is understood, however, that the present invention also includes using a different number of electrodes (e.g., 2 or 3 electrodes, or more than 4 electrodes). In one example, a first conductor of multiconductor lead 110 electrically couples a first electrode, such as tip electrode 120 (e.g., disposed at the apex of the right ventricle of heart 115), to device 105. A second conductor of multiconductor lead 110 independently electrically couples a second electrode, such as ring electrode 125, to device 105. In one embodiment, device 105 includes a hermetically sealed housing 130, formed from a conductive metal, such as titanium. Housing 130 (also referred to as a “case” or “can”) is substantially covered over its entire surface by a suitable insulator, such as silicone rubber, except for at a window that forms a third electrode, referred to as a “case” or “can” electrode 135. In one embodiment, a header 140 is mounted on housing 130 for receiving lead 110. Header 140 is formed of an insulative material, such as molded plastic. Header 140 also includes at least one receptacle, such as for receiving lead 110 and electrically coupling conductors of lead 110 to device 105. Header 140 also includes a fourth electrode, referred to as indifferent electrode 145.
  • FIG. 1 also illustrates generally portions of [0038] device 105, together with schematic illustrations of connections to the various electrodes. Device 105 includes an electrical stimulation source, such as exciter 150. Exciter 150 delivers an electrical excitation signal, such as a strobed sequence of current pulses or other measurement stimuli, to heart 115 (e.g., between ring electrode 125 and tip electrode 120, or using any other electrode configuration suitable for delivering the current pulses). In response to the excitation signal provided by exciter 150, a response signal is sensed by signal processor 155 (e.g., between tip electrode 120 and indifferent electrode 145, or any other suitable electrode configuration).
  • In one embodiment, the response signal sensed by [0039] signal processor 155 is a voltage that represents a transthoracic (i.e., across a portion of the chest or thorax) impedance. A minute ventilation signal (also referred to as “minute volume” or “MV”) signal is derived from the impedance signal, as illustrated above by Equation 1. A larger MV signal indicates a metabolic need for an increased heart rate. According to one aspect of the invention, signal processor 155 extracts ventilation information, including the MV signal, from the impedance signal. Based on the MV signal, signal processor 155 outputs an indicated rate signal at node 160 to controller 165. Based on the indicated rate signal at node 160, controller 165 adjusts the rate of delivery of cardiac rhythm management therapy, such as electrical pacing stimuli, to heart 115 by therapy circuit 170. Such pacing stimuli includes, for example, providing bipolar pacing between tip electrode 120 and ring electrode 125, providing unipolar pacing between can electrode 135 and either of tip electrode 120 or ring electrode 125, or providing pacing stimuli using any other suitable electrode configuration.
  • Exciter and Resulting Stimuli Waveform
  • FIG. 2 is a schematic/block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of particular circuits included within [0040] exciter 150 for delivering electrical stimuli (e.g., strobed alternating-direction constant-amplitude current pulses) to heart 115. Exciter 150 includes, among other things, bridge switcher 200, comprising switches 200A, 200B, 200C, and 200D. In one embodiment, switches 200A-D are implemented as transistors, such as p-channel metal-oxide semiconductor (PMOS) field-effect transistors (FETs), or any other suitable switches.
  • [0041] Exciter 150 also includes current source 205 and current sink 210. In one embodiment, each of current source 205 and current sink 210 include transistors in a regulated cascode or other suitable configuration. In one embodiment, switcher 200 is electrically coupled to case electrode 135 and ring electrode 125 through respective dc blocking capacitors 215A and 215B and respective switches 220A and 220B (e.g., PMOS transistors). Switches 225A and 225B (e.g., PMOS transistors) precharge respective capacitors 215A and 215B. Exciter 150 also includes a clock circuit 230 receiving one or more clock or other control signals from controller 165 and providing signals to the control terminals of each of switches 200A-D, 220A-B, and 225A-B.
  • FIG. 3 illustrates generally a [0042] current waveform 300 between case electrode 135 and ring electrode 125 resulting from operation of exciter 150 according to one aspect of the present invention. According to one aspect of the invention, waveform 300 includes a multiple phase (“multiphase”) stimulus. In one embodiment, the multiphase stimulus includes a square wave, such as four current pulses 301, 302, 303, and 304 in sequentially alternating polarity/direction, each current pulse being a phase of the multiphase stimulus. In one embodiment, by way of example, but not by way of limitation, each one of current pulses 301-304 has a duration that is selected at approximately between 1 and 100 microseconds (e.g., approximately between 2 and 60 microseconds, such as at 20 microseconds), to allow adequate sampling of the transthoracic impedance signal obtained in response thereto. In the embodiment illustrated in FIG. 3, pulses 301-304 form a square wave having a carrier frequency of approximately 25 kilohertz. Other suitable durations of current pulses 301-304 could also be used, providing a different resulting carrier frequency. According to another aspect of the invention, the sequence of current pulses 301-304 is strobed. In one embodiment, by way of example, but not by way of limitation, the four pulse sequence 301-304 is repeated at a strobing frequency (also referred to as a repetition frequency or a sampling frequency) of approximately 20 Hertz (i.e., a 50 millisecond time interval). Other suitable strobing/repetition frequencies could also be used. For example, but not by way of limitation, any strobing/repetition time interval shorter than 55 milliseconds could be used.
  • The amplitude of current pulses [0043] 301-304 was selected at less than approximately 1 milliampere. For example, approximately 320 microampere amplitude current pulses 301-304 provide an adequate excitation signal to obtain the desired response signal, while minimizing current drain of the implanted device 105, thereby increasing its implanted longevity. However, other amplitudes of current pulses 301-304 could also be used. Such amplitudes of current pulses 301-304 should be less than the tissue stimulation threshold of the heart to avoid any resulting cardiac depolarization. The strobing frequency is sufficiently fast to provide adequate sampling of ventilation or other information carried by the transthoracic impedance signal obtained in response to the electrical stimuli provided by exciter 150. Such ventilation information can appear at frequencies as high as approximately 1 Hertz, depending on the patient's breathing rate. The strobing frequency also minimizes aliasing of a “stroke volume” component of the transthoracic impedance signal (i.e., a portion of the transthoracic impedance signal that varies along with the patient's heartbeat instead of the patient's breathing rate). The stroke volume component of the transthoracic impedance signal can have frequencies as high as approximately 3 Hertz, depending on the patient's heart rate.
  • Prior to each sequence of current pulses [0044] 301-304, dc blocking capacitors 215A-B are precharged by a bias circuit, such as by turning on switches 200A-D and 225A-B, with switches 220A-B being off. Current source 205 and current sink 210 establish the operating point of a terminal of each of dc blocking capacitors 215A-B that is coupled to switcher 200. After precharging, switches 225A-B are turned off. Next, pulse 301 is produced by turning on switches 200A, 200D, and 220A-B, such that current delivered by current source 205 leaves case electrode 135. The current returns through ring electrode 125, and is sunk by current sink 210. Next, pulse 302 is produced by turning on switches 200B-C and 220A-B, such that current delivered by current source 205 leaves ring electrode 125. The current returns through case electrode 135, and is sunk by current sink 210. Next, pulse 303 is produced by again turning on switches 200A, 200D, and 220A-B, such that current delivered by current source 205 leaves case electrode 135. The current returns through ring electrode 125, and is sunk by current sink 210. Next, pulse 304 is produced by again turning on switches 200B-C and 220A-B, such that current delivered by current source 205 leaves ring electrode 125. The current returns through case electrode 135, and is sunk by current sink 210. Switches 220A-B, 200A-D, and 225A-B are turned off until precharging for another four current pulse sequence 301-304, which is delivered approximately 50 milliseconds later, as illustrated in FIG. 3.
  • According to one aspect of the invention, [0045] clock circuit 230 provides nonoverlapping control signals to switches 225A-B and switches 220A-B. As a result, switches 225A-B are not turned on at the same time as switches 220A-B. This avoids any coupling of either of case electrode 135 and ring electrode 125 to the positive power supply voltage VDD.
  • [0046] Waveform 300 provides several important advantages allowing efficient and accurate sensing of the MV signal, allowing system 100 to provide more effective delivery of rate-responsive cardiac rhythm management therapy to the patient. First, system 100 allows the use of relatively low amplitude current pulses (e.g., +/−320 microamperes). This conserves power, allowing battery-powered portions of system 100 (e.g., device 105) to remain implanted in the patient for a longer usable lifetime. Because of their low amplitude, current pulses 301-304 do not produce any discernable artifacts on electrocardiogram (ECG) traces or on other diagnostic equipment. Such artifacts can confuse diagnosing physicians. The low amplitude current pulses 301-304 are also less likely to trigger false detection of intrinsic heart activity, such as by sense amplifiers included in device 105. False detection of intrinsic heart activity can inhibit proper delivery of pacing therapy, rendering cardiac rhythm management ineffective and increasing risk to the patient. According to one aspect of the present invention, the sensitivity setting of such sense amplifiers can be increased without being affected by interference from the current pulses 301-304 produced by exciter 150. Moreover, the low amplitude current pulses 301-304 avoid the risk of capturing heart 115 (i.e., inducing an electrical depolarization and heart contraction), particularly when current pulses 301-304 are delivered from small electrodes that are also used for delivering pacing therapy to heart 115.
  • According to another aspect of the invention, [0047] waveform 300 includes current pulses 301-304 that are strobed at a frequency of approximately 20 Hertz. The 25 kilohertz carrier frequency is only present for a short fraction of the 50 millisecond strobing time interval (i.e., duty cycle of less than 1%). The strobing also reduces power consumption and obtains increased implanted longevity of device 105, as described above.
  • Waveform [0048] 300 also provides balance in both amplitude and duration for each polarity/direction of the current pulses 301-304, thereby balancing the charge delivered to heart 115. Each +320 microampere pulse (e.g., 301 and 303) is balanced by an equal duration corresponding −320 microampere pulse (e.g., 302 and 304). This method of balancing the amplitude and duration of waveform 300 reduces the likelihood of capturing heart 115 or inducing false sensing as intrinsic heart activity sensed by device 105.
  • Interference Avoidance
  • In one embodiment, [0049] device 105 avoids delivering the multiphase stimulus in the presence of other interfering signals, such as telemetry signals, that increase the difficulty of accurately detecting a response. Referring again to FIG. 1, in one embodiment, device 105 includes a telemetry transceiver 185 for communicating via telemetry signals (e.g., telemetry pulses) with an external programmer 190, such as by inductively coupled coils in each of the device 105 and the external programmer 190. When telemetry pulses are detected by the telemetry receiver in device 105, and scheduled delivery of the multiphase stimulus coincides with the detection of the telemetry pulses, controller 165 delays delivery of the multiphase stimulus (e.g., current pulses 301-304), such as by approximately 1 millisecond. This avoids inaccuracies in the response signal to current pulses 301-304 that may result from the telemetry pulses or, similarly, from the presence of other interfering signals.
  • Signal Processor
  • FIG. 4 is a block diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of portions of [0050] signal processor 155. Signal processor 155 includes analog signal processing circuit 400 and digital signal processing circuit 405. Inputs of a preamplifier 410 (also referred to as a preamp or a receiver) of analog signal processing circuit 400 are electrically coupled to each of indifferent electrode 145 and tip electrode 120 for receiving a signal in response to the above-described stimuli provided by exciter 150. Analog signal processing circuit 400 also includes demodulator 415, receiving the output of preamplifier 410, and providing an output signal to bandpass filter 420. An output signal from bandpass filter 420 is received by analog-to-digital (AID) converter 425. An output signal from A/D converter 425 is received at highpass filter 430 of digital signal processing circuit 405.
  • In one embodiment, digital [0051] signal processing circuit 405 is included within controller 165 such as, for example, as a sequence of instructions executed by a microprocessor. In another embodiment, digital signal processing circuit 405 includes separately implemented hardware portions dedicated to performing the digital signal processing tasks described below. An output signal from highpass filter 430 is received by adaptive lowpass filter 435 of digital signal processing circuit 405. Minute ventilation calculation module 440 receives an output signal from adaptive lowpass filter 435, and provides a resulting indicated rate signal at node 160 to controller 165.
  • Preamplifier
  • FIG. 5 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of [0052] preamplifier 410. Preamplifier 410 includes a switched-capacitor (SC) differential amplifier 500. Preamplifier 410 is electrically coupled to indifferent electrode 145 and tip electrode 120 through respective switches 510 and 515 and respective resistors 520 and 525. Switches 510 and 515 are turned on only during the approximate time when the stimuli current pulses 301-304 are being delivered by exciter 150. Resistors 520 and 525 provide antialiasing/bandlimiting of the input signals received from indifferent electrode 145 and tip electrode 120.
  • [0053] Differential amplifier 500 includes input capacitors 530 and 535, coupled to resistors 520 and 525 respectively, and also coupled to a respective positive input at node 540 and a negative input, at node 545, of a differential-input/differential-output operational amplifier 550. Feedback capacitors 560 and 565 are coupled from a respective negative output, at node 570, and a positive output, at node 575, of operational amplifier 550, to its respective positive input, at node 540, and negative input, at node 545. In one embodiment, input capacitors 530 and 535 have approximately 10 times the capacitance value of respective feedback capacitors 560 and 565.
  • [0054] Differential amplifier 500 also includes autozeroing input switches, 580 and 585, coupling respective input nodes 540 and 545 to respective reference voltages (e.g., a ground voltage). Autozeroing output switches 590 and 595 couple respective output nodes 570 and 575 to respective reference voltages (e.g., a ground voltage). Switches 580, 585, 590, and 595 provide zeroing of corresponding feedback capacitors 560 and 565. Switches 580 and 585 further establish the bias points of the input nodes 540 and 545 of operational amplifier 550, such as during sampling of signals from indifferent electrode 145 and tip electrode 120 onto input capacitors 530 and 535.
  • [0055] Preamplifier 410 receives a voltage based on the transthoracic impedance between indifferent electrode 145 and tip electrode 120. For example, a transthoracic impedance of 50 ohms results in a voltage between the inputs of differential amplifier 500 of approximately 16 millivolts. The transthoracic impedance varies as the patient breathes, increasing as air fills the patient's thoracic cavity during inspiration and decreasing as air is released during expiration. The transthoracic impedance may vary, for example, by approximately 2 ohms during respiration, resulting in an approximately 0.64 millivolt modulation of the approximately 16 millivolt baseline signal appearing between the inputs of differential amplifier 500. These impedance and voltage values are recited by way of example only; actual impedance and voltage values will vary according to, among other things, differences in patient anatomy and electrode placement.
  • In one embodiment of the invention, by way of example, but not by way of limitation, the electrodes used for delivering the excitation current (e.g., [0056] ring electrode 125 and case electrode 135) are different from the electrodes used for sensing the response thereto (e.g., indifferent electrode 145 and tip electrode 120). This advantageously reduces the magnitude of the baseline component of the transthoracic impedance signal, thereby increasing the relative contribution of the ventilation component of the transthoracic impedance signal, and increasing the signal-to-noise ratio (SNR). Alternatively, the same electrodes could be used for delivering the excitation current and sensing the response thereto.
  • In one embodiment, [0057] differential amplifier 500 provides an effective voltage gain of approximately 6. In the above example, the 16 millivolt baseline signal is amplified to approximately 100 millivolts by differential amplifier 500 and the resulting signal is provided to demodulator 415.
  • Demodulator
  • [0058] Demodulator 415 samples the signal obtained in response to current pulses 301-304 after the above-described amplification by preamplifier 410. According to one aspect of the invention, the output of preamplifier 410 is sampled at the end of each of current pulses 301-304. Demodulator 415 combines these four samples into a single value using a weighted average. The resulting weighted average represents the total impedance (i.e., including both baseline and ventilation components) obtained for the sequence of four current pulses 301-304.
  • In one embodiment, the weighted average is formed by weighting the second and third samples, obtained from respective [0059] current pulses 302 and 303, by a factor of approximately 3.0 relative to the first and fourth samples, obtained from respective current pulses 301 and 304. Weighting the samples advantageously provides an additional highpass filtering function, substantially transmitting the transthoracic impedance signal at the 25 kilohertz carrier frequency of the current pulses 301-304, while substantially rejecting out-of-band signals. In particular, demodulator 415 provides additional rejection of low-frequency signals, such as R-waves and other electrical signals produced by heart 115. A transfer function provided by one embodiment of demodulator 415, is described in the z-domain, as illustrated in Equation 2.
  • H(z)=0.219(z −3−3z −2+3z −1−1)  (2)
  • In this embodiment, [0060] demodulator 415 provides a voltage gain that is approximately between 1.75 and 2.0 for the in-band transthoracic impedance signal. Moreover, demodulator 415 also advantageously attenuates signals at frequencies below 100 Hz by a factor of at least approximately 120 dB, including such signals as R-waves and other electrical intrinsic heart activity signals produced by heart 115, which can interfere with sensing the patient's transthoracic impedance.
  • FIG. 6 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of a switched-[0061] capacitor demodulator 415. The output signal from preamplifier 410 is sampled onto capacitors 600A-B in response to current pulse 301, onto capacitors 605A-B in response to current pulse 302, onto capacitors 610A-B in response to current pulse 303, and onto capacitors 615A-B in response to current pulse 304. Capacitors 605A-B and 610A-B provide 3 times the capacitance value of capacitors 600A-B and 615A-B, in order to provide the above-described weighting of the samples. After the weighted sampling of the output of preamplifier 410 in response to the four current pulses 301-304, these weighted samples are summed by switched-capacitor integrator 620 (also referred to as a summer).
  • Also illustrated in FIG. 6 are [0062] dummy capacitors 625A-B. Each of dummy capacitors 625A-B has a capacitance value that is twice that of one of capacitors 600A-B, and twice that of one of capacitors 615A-B. Dummy capacitors 625A-B are switched in during sample of current pulses 301 and 304. As a result, demodulator 415 presents the same load capacitance to preamplifier 410 during sampling of each of the four current pulses 301-304. As seen in FIG. 6, however, the charge that is sampled onto dummy capacitors 625A-B is not included in the weighted sample (i.e., the resulting charge is not included in the integration provided by integrator 620). Furthermore, it is understood that, in one embodiment, the capacitors illustrated in FIG. 6 are initialized (e.g., discharged) prior to sampling any particular sequence of current pulses 301-304.
  • In FIG. 6, [0063] integrator 620 includes input capacitors 650 and 655, which are autozeroed by switches, as illustrated, during the clock phase φAZ. An integration capacitor 660, which is in the feedback path around operational amplifier 665, sums the weighted samples obtained in response to the four current pulses 301-304 during an integration clock phase φI. A noise sampling/integration capacitor 630, which is also in the feedback path around operational amplifier 665, sums the weighted samples obtained in the absence of delivered current pulses during a noise integration clock phase φNI, as described below. Integrator 620 also provides a matching network 670 on the other input of operational amplifier 665 for matching the above-described switched capacitor operation.
  • In one embodiment, [0064] demodulator 415 also provides a noise sensing mode of operation. In normal operation, demodulator 415 samples the output of filter/amplifier 410 in response to current pulses 301-304 provided by exciter 150. During a noise sensing mode of operation, exciter 150 is turned off (i.e., current pulses 301-304 are not provided), and demodulator 415 samples, onto switched-in noise sampling/integration capacitor 630, noise arising from external sources (e.g., heart signals or any environmental noise sources) and internal noise produced by circuits coupled to the input of the demodulator 415. In particular, demodulator 415 is capable of sensing noise that is at frequencies close to the 25 kilohertz carrier frequency of the current pulses 301-304.
  • In one embodiment, the gain of [0065] demodulator 415 is increased (e.g., by a factor of approximately 2.0-2.5) during noise sensing mode in order to provide more sensitive noise detection. For example, the noise sampling/integration capacitor 630 used during noise sensing is different in value from a corresponding integration capacitor used during normal operation of demodulator 415, in order to provide a different gain during noise sensing.
  • According to one aspect of the invention, [0066] device 105 also includes a noise reversion circuit based on the noise sensed by demodulator 415 when exciter 150 is turned off. A noise comparator 635 receives a signal derived from the output of demodulator 415. Comparator 635 determines whether the detected noise exceeds a particular programmable threshold value. If the detected noise exceeds the threshold value, subsequent circuits ignore the output of demodulator 415 (e.g., until the detected noise again falls below the threshold value). In one embodiment, the programmable threshold value used by comparator 635 is implemented as a programmable switched-capacitor array, providing threshold voltages ranging between approximately 4-120 millivolts at the output of demodulator 415 (corresponding to an impedance noise threshold between approximately 0.4-12 ohms).
  • Bandpass Filter
  • In one embodiment, [0067] bandpass filter 420 provides a passband between single pole corner frequencies at 0.1 Hz and 2.0 Hz, and includes a gain stage providing a voltage gain that is programmable (e.g., 6×, 12×, and 24×). The 0.1 Hz low frequency (highpass) pole substantially attenuates the baseline component of the transthoracic impedance signal, but substantially transmits the time-varying component of the transthoracic impedance signal representing ventilation. The 2.0 Hz high frequency (lowpass) pole substantially attenuates other time-varying components of the transthoracic impedance signal that do not contribute substantial ventilation information. In particular, the lowpass pole effectively contributes to the attenuation of signal components due to the cardiac stroke signal resulting from the beating of heart 115. As described above, removal of the stroke signal is both difficult and particularly important for properly adapting the delivered pacing rate based on minute ventilation, since the stroke signal is very close in frequency to the desired ventilation signal. The lowpass pole also filters out other noise at frequencies that exceed the lowpass pole frequency.
  • Many different implementations of [0068] bandpass filter 420 will be suitable for use in the present invention. In one embodiment, bandpass filter 420 includes a switched-capacitor biquadratic filter stage, series-coupled with a subsequent switched-capacitor gain stage. Capacitance values of the switched-capacitor gain stage are user-programmable, thereby obtaining differing voltage gains, as described above. The output of the switched capacitor gain stage included in bandpass filter 420 is provided to the input of A/D converter 425.
  • Analog-to-Digital (A/D) Converter
  • A/[0069] D converter 425 receives the output signal of bandpass filter 420 and provides a resulting digitized output signal to highpass filter 430 of digital signal processing circuit 405. In one embodiment, A/D converter 425 is implemented as an 8-bit, successive approximation type switched-capacitor A/D converter having an input range of approximately 1 Volt. According to one aspect of the invention, A/D converter 425 provides one 8-bit digital word corresponding to each sequence of four current pulses 301-304 delivered by exciter 150. Many different implementations of A/D converter 425 will be suitable for use in the present invention. For example, a different A/D converter resolution (greater than or less than 8 bits) may be used.
  • Digital Signal Processing Circuit
  • [0070] Highpass filter 430 includes, in one embodiment, a single-pole infinite impulse response (IIR) digital filter that receives the 8-bit digital output signal from A/D converter 425, removing frequency components below its highpass cutoff frequency of approximately 0.1 Hz. Many other different embodiments of highpass filter 430 will also be suitable for use in the present invention. Highpass filter 430 advantageously further attenuates baseline dc components of the transthoracic impedance and any dc offset voltages created by A/D converter 425. The output of highpass filter 430 is provided to adaptive lowpass filter 435.
  • [0071] Adaptive lowpass filter 435 receives the output signal of highpass filter 430 and attenuates frequency components of the signal that exceed the lowpass cutoff frequency of adaptive lowpass filter 435. Attenuated frequencies include the cardiac stroke signal, resulting from changes in blood volume in heart 115 as it contracts during each cardiac cycle, which appears as a component of the transthoracic impedance signal. Thus, the cardiac stroke signal confounds the desired ventilation information indicating the metabolic need for adjusting pacing rate.
  • As described above, the component of the transthoracic impedance due to the stroke signal can be substantial. As a result, attenuation of the stroke signal is particularly important for properly adapting the delivered pacing rate based on minute ventilation. Moreover, the stroke signal is difficult to attenuate, since it is very close in frequency to the desired ventilation signal. Furthermore, the frequencies of each of the stroke and ventilation signals varies according to the patient's activity, making the stroke and ventilation signals difficult to separate. [0072]
  • [0073] Adaptive lowpass filter 435 provides effective attenuation of the stroke component of the processed transthoracic impedance signal received from highpass filter 430. Frequency components above a lowpass cutoff frequency are attenuated. In one embodiment, the frequency components above the lowpass cutoff frequency are attenuated by at least 30 decibels while preserving ventilation information having frequency components below the lowpass cutoff frequency. The lowpass cutoff frequency is adaptively based on a heart rate of the patient and, according to a further aspect of the invention, is independent of any breathing rate signal obtained from the patient. In one embodiment, the patient's heart rate is detected by sense amplifiers 175, and provided to adaptive lowpass filter 435, such as by controller 165, for adjusting the lowpass cutoff frequency of adaptive lowpass filter 435 accordingly. Table 1 illustrates, by way of example, but not by way of limitation, one mapping of different lowpass cutoff frequencies of adaptive lowpass filter 435 to ranges of the patient's heart rate. Other mappings may also be used.
    TABLE 1
    Exemplary lowpass cutoff frequencies of adaptive lowpass filter 435
    based on different sensed heart rates.
    Heart Rate (beats per minute) Lowpass cutoff frequency
    <68 0.5 Hz
    68-88  0.75 Hz
    >88 1.0 Hz
  • As Table 1 illustrates, a 0.5 Hz cutoff frequency is used when the sensed heart rate is less than 68 beats per minute. When the patient's heart rate increases above 68 beats per minute, [0074] adaptive lowpass filter 435 switches its lowpass cutoff frequency to 0.75 Hz. When the patient's heart rate increases above 88 beats per minute, adaptive lowpass filter 435 switches its lowpass cutoff frequency to 1.0 Hz. Similarly, as heart rate decreases, adaptive lowpass filter 435 adjusts the lowpass cutoff frequency according to Table 1. As a result, adaptive lowpass filter 435 preserves the ventilation information at higher breathing rates (breathing rate increases together with heart rate), while continuing to attenuate the stroke signal.
  • The present invention bases adaptive adjustment of the lowpass cutoff frequency only on heart rate. Among other things, this reduces computational complexity and power consumption associated with monitoring the breathing rate for adjusting the lowpass cutoff frequency. This also ensures that [0075] adaptive lowpass filter 435 removes the stroke signal for all particular combinations of respiration rate and heart rate, so that pacing rate is appropriately adjusted based on minute ventilation.
  • In one embodiment, [0076] adaptive filter 435 uses a 4-pole Chebyshev filter that is better suited to data represented by fewer bits (e.g., 8-bit fixed point arithmetic). This conserves power and avoids instability and other potential problems of quantization. According to one aspect of the invention, adaptive lowpass filter 435 uses a state-space structure, rather than in a conventional direct form structure. The state-space structure further reduces the effects of coefficient quantization and roundoff noise. One example of such a state-space structure is described in Leland B. Jackson, “Digital Filters and Signal Processing,” 2nd ed., pp. 332-340, Kluwer Academic Publishers, Boston, Mass., the disclosure of which is incorporated herein by reference.
  • FIG. 7 is a signal flow diagram illustrating generally one embodiment of [0077] adaptive filter 435 having a state-space topology. FIG. 7 includes scaling elements, delay elements, and summation elements. Signals output from summation elements are also scaled, as illustrated in FIG. 7. As with any DSP filter, saturation of signals at particular nodes should be avoided by adjusting the coefficients according to conventional DSP coefficient scaling techniques. One embodiment of hexadecimal values of filter coefficients is illustrated by way of example, but not by way of limitation, in Table 2.
  • [0078] Adaptive lowpass filter 435 outputs a signal based on transthoracic impedance and carrying ventilation information. The stroke component of the transthoracic impedance signal is substantially removed. The output of adaptive lowpass filter 435 is provided to MV calculation module 440, which calculates a minute ventilation indicated pacing rate based on the ventilation information.
    TABLE 2
    Exemplary Scaling Coefficients for Adaptive Filter 435
    Coefficient for Coefficient for Coefficient for
    Scaling 0.5 Hz Lowpass 0.75 Hz Lowpass 1.0 Hz Lowpass
    Element Cutoff Frequency Cutoff Frequency Cutoff Frequency
    (Hexadecimal) (Hexadecimal) (Hexadecimal) (Hexadecimal)
    1B1 40 22 28
    1B2 00 00 00
    1A11 77 75 72
    1A12 EE C6 9B
    1A21
    02 05 05
    1A22 3C 3B 39
    1C1 01 FE FF
    1C2 40 60 7A
    1D
    04 18 15
    2B1 20 10 0F
    2B2 00 01 01
    2A11 3E 33 2F
    2A12 C3 FD FD
    2A21
    01 0C 18
    2A22 3E 33 2F
    2C1 00 02 06
    2C2 40 3A 3D
    2D 10 05 07
  • Minute Ventilation Calculation Module
  • In one embodiment, [0079] MV calculation module 440 is implemented as a sequence of instructions executed on any suitable microprocessor, such as a Zilog Z80-type microprocessor. Alternatively, MV calculation module 440 is implemented as any other hardware or software configuration capable of calculating an indicated pacing rate based on ventilation information. One example of such a sequence of instructions executed on a microprocessor for calculating a minute ventilation indicated rate is described below, and illustrated in the flow chart of FIG. 8.
  • [0080] MV calculation module 440 receives from adaptive lowpass filter 435 a digital signal representing a time-varying transthoracic impedance. In one embodiment, the impedance signal is centered around zero, with positive values representing inhalation, and negative values representing exhalation. At step 800, the maximum (most positive) and minimum (most negative) values of the impedance signal are stored in separate storage registers. After each breath, an interrupt is provided to the microprocessor, such as upon each positive-going zero-crossing.
  • At [0081] step 805, the tidal volume (TV) is calculated upon receiving the interrupt. The tidal volume is obtained by reading the storage registers, and taking the difference between the maximum and minimum values of the impedance signal held for the patient's previous breath. A larger tidal volume indicates a deeper breath than a smaller tidal volume. A tidal volume data point is produced at step 805 for each breath by the patient.
  • At [0082] step 810, the tidal volume is integrated (i.e., the tidal volume data points are summed) for a predetermined period of time (e.g., approximately 8 seconds), obtaining a minute ventilation data point, as described in Equation 1. After each 8 second integration period, the minute ventilation data point is output, and a new integration (i.e., summation) of tidal volume commences.
  • [0083] Steps 815 and 820, include carrying out concurrent moving short term and long term averages, respectively. More particularly, the short term average (“STA,” also referred to as a “boxcar” average) at step 815 represents, at a particular point in time, a moving average of the minute ventilation data points over the previous approximately 32 seconds. The short term average represents the present minute ventilation indication of metabolic need. Similarly, the long term average (“LTA”) at step 820 represents, at a particular point in time, a moving average of the minute ventilation data points over the previous approximately 2 hours. The long term average approximates the resting state of the minute ventilation indicator. In one embodiment, the long term average at step 820 is carried out by an IIR digital filter.
  • At step [0084] 825, the short term and long term averages are compared. In one embodiment, this comparison involves subtracting the long term average from the short term average. The difference is optionally scaled, and used to adjust the pacing rate when the short term average exceeds the long term average. In one embodiment, the rate is adjusted according to Equation 3.
  • RATEMV =LRL+K(STA−LTA)  (3)
  • In [0085] Equation 3, STA represents the short term average, LTA represents the long term average, K represents an optional scaling coefficient, LRL is a programmable lower rate limit to which the incremental sensor driven rate is added, and RATEMV is the minute ventilation indicated rate at which pacing therapy is delivered. In this embodiment, RATEMV is a linear function of the difference STA-LTA. Also, in this embodiment, if the value of the short term average is less than the value of the long term average, pacing therapy is delivered at the lower rate limit (LRL).
  • In one embodiment of the invention, more than one scaling coefficient K is used, obtaining a piecewise linear mapping of minute ventilation to the resulting minute ventilation indicated rate. For example, when the STA-LTA difference exceeds a certain threshold value, a smaller scaling coefficient K is used. This reduces the incremental increase in pacing rate for high pacing rates, when compared to the incremental increase in pacing rate for pacing rates close to the lower rate limit (LRL). [0086]
  • Step [0087] 825 is alternatively implemented as a ratio STA/LTA, rather than the difference STA-LTA. In one such embodiment, the rate is adjusted according to Equation 4 when STA exceeds LTA. RATE MV = LRL + C ( STA LTA ) ( 4 )
    Figure US20030105499A1-20030605-M00001
  • In Equation 4, STA represents the short term average, LTA represents the long term average, C represents an optional scaling coefficient, LRL is a programmable lower rate limit to which the incremental sensor driven rate is added, and RATE[0088] MV is the minute ventilation indicated rate at which pacing therapy is delivered. If the value of the short term average is less than the value of the long term average, pacing therapy is delivered at the lower rate limit (LRL). In this embodiment, reduced incremental rate at high pacing rates is obtained by using more than one scaling coefficient, as described above.
  • Other rate modifiers can also be used to obtain a minute ventilation indicated rate. Moreover, the minute ventilation indicated rate can be combined, blended, or otherwise used in conjunction with other rate indicators, such as those derived from different sensors providing different indicators of metabolic need (e.g., acceleration). Such indicators may have different response characteristics (e.g., time lag after onset of exercise) that are advantageously combined with the minute ventilation rate indication described above. [0089]
  • At [0090] step 830, the indicated rate (e.g., RATEMV) is provided to controller 165, for adjusting the rate of pacing therapy delivered by therapy circuit 170.
  • Minute Ventilation Calculation Alternate Embodiment
  • FIG. 9 is a flow chart, similar to that of FIG. 8, illustrating generally another embodiment of the invention that uses a breath-by-breath minute ventilation calculation. At [0091] step 900, time differences corresponding to the peaks and valleys of the response signal are used to obtain respiration period data points corresponding to the tidal volume data points obtained in step 805. At step 910, a breath-by-breath indication of minute ventilation is obtained, such as by dividing the tidal volume data points by the corresponding respiration period data points to obtain minute ventilation data points. The rate of delivering cardiac rhythm management therapy is then adjusted based on the minute ventilation data points, as described above with respect to FIG. 8.
  • Signal Processor Alternate Embodiment
  • The above description illustrates, by way of example, but not by way of limitation, a particular embodiment of the [0092] signal processor 155, as illustrated in FIG. 4, and methods for its use. Many other possible embodiments of signal processor 155 exist and are also included within the present invention. FIG. 10 is a block diagram illustrating generally one such variation on signal processor 155. The bandpass filter 420 of FIG. 4 is implemented digitally in the signal processor 155 of FIG. 10. Other variations are also possible without departing from the present invention.
  • Rate Adjustment Alternate Embodiment
  • The above description illustrates, by way of example, but not by way of limitation, a particular embodiment of the present invention in which ventilation information is extracted from a detected transthoracic impedance, and the rate of delivery of cardiac rhythm management therapy is adjusted based on an indicator derived from the ventilation information. However, the present invention also includes the extraction of other information (e.g., cardiac stroke information) from the transthoracic impedance, such as for adjusting the rate of delivery of cardiac rhythm management therapy based on an indicator extracted from such information. One such example is disclosed in Warren et al. U.S. Pat. No. 5,156,147 entitled, “VARIABLE RATE PACEMAKER HAVING UPPER RATE LIMIT GOVERNOR BASED ON HEMODYNAMIC PERFORMANCE,” which is assigned to the assignee of the present invention, and the disclosure of which is incorporated herein by reference. Another such example is disclosed in Spinelli U.S. Pat. No. 5,235,976 entitled, “METHOD AND APPARATUS FOR MANAGING AND MONITORING CARDIAC RHYTHM MANAGEMENT USING ACTIVE TIME AS THE CONTROLLING PARAMETER,” which is assigned to the assignee of the present invention, and the disclosure of which is incorporated herein by reference. [0093]
  • Conclusion
  • The present invention provides, among other things, a cardiac rhythm management device that senses transthoracic impedance and adjusts a delivery rate of the cardiac rhythm management therapy based on information extracted from the transthoracic impedance. In one embodiment, an adaptive lowpass filter removes the stroke signal from the transthoracic impedance signal while preserving the ventilation information. The adaptive filter includes a lowpass cutoff frequency that is adaptively based on the patient's heart rate, but independent of a breathing rate signal. A weighted demodulation provides filtering that enhances rejection of unwanted signals. Minute ventilation is obtained from tidal volume obtained from the ventilation information. An indicated rate is based on a difference between, or ratio of, short and long term averages of the minute ventilation information, unless noise exceeding a threshold is detected. [0094]
  • The present invention effectively manages the patient's heart rate based on an accurate indication of metabolic need. It provides robust operation in the presence of extraneous noise signals that confound the indication of metabolic need. It also provides low power consumption, increasing the usable life of the battery-powered implantable device. [0095]
  • It is to be understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. [0096]

Claims (20)

What is claimed is:
1. A method of determining transthoracic impedance in a cardiac rhythm management device, the method comprising:
repeatedly delivering a multiple phase stimulus to a thorax region of a patient; and
demodulating more than one phase of the multiple phase stimuli to obtain sample points of a response signal including transthoracic impedance information.
2. The method of claim 1, in which demodulating includes sampling a response to each phase of the multiple phase stimulus, and combining the sampled responses.
3. The method of claim 2, in which sampling the response includes weighting the samples to obtain a filtering function.
4. The method of claim 1, in which repeatedly delivering a multiple phase stimulus includes repeatedly delivering an at least four phase stimulus.
5. The method of claim 4, in which demodulating includes sampling a response to each phase of the multiple phase stimulus, combining the sampled responses, and weighting second and third samples more than first and fourth samples responsive to the at least four phase stimulus.
6. The method of claim 5, in which weighting includes weighting each of second and third samples approximately 3 times more than each of first and fourth samples responsive to the four phase stimulus.
7. The method of claim 1, further comprising adjusting a rate of delivering cardiac rhythm management therapy based on ventilation information included in the transthoracic impedance information of a plurality of the sample points.
8. The method of claim 7, further comprising:
demodulating a noise-response signal in the absence of the stimuli;
comparing the noise-response signal to a threshold value to determine whether the noise-response signal exceeds the threshold value; and
wherein the step of adjusting a rate of delivering cardiac rhythm management therapy includes delivering the cardiac rhythm management therapy independent of the ventilation information when the noise-response signal exceeds the threshold value.
9. The method of claim 1, in which repeatedly delivering a multiple phase stimulus includes repeatedly delivering a multiple phase stimulus having alternating polarity phases.
10. The method of claim 9, in which delivering a multiple phase stimulus includes repeatedly delivering a multiple phase stimulus having alternating direction current pulse phases.
11. The method of claim 1, in which repeatedly delivering a multiple phase stimulus includes repeatedly delivering a square wave stimulus.
12. The method of claim 1, in which repeatedly delivering a multiple phase stimulus includes repeatedly delivering a square wave including four alternating direction current pulses having an amplitude magnitude that is less than a tissue stimulation threshold.
13. The method of claim 1, in which the amplitude magnitude is less than approximately 1 milliampere.
14. The method of claim 13, in which the amplitude magnitude is approximately 320 microamperes.
15. The method of claim 1, in which the duration of each phase of the multiple phase stimulus is approximately between 1 and 100 microseconds.
16. The method of claim 15, in which the duration of each phase of the multiple phase stimulus is approximately 20 microseconds.
17. The method of claim 1, in which repeatedly delivering a multiple phase stimulus includes waiting for a time period between successive deliveries of the multiple phase stimulus.
18. The method of claim 17, in which the time period is less than approximately 55 milliseconds.
19. The method of claim 1, further comprising:
detecting an interference signal; and
delaying delivery of the multiple phase stimulus when the interference signal is detected.
20. The method of claim 19, in which detecting an interference signal includes detecting a telemetry signal, and delaying delivery of the multiple phase stimulus when the interference signal is detected includes delaying delivery of the multiple phase stimulus when the telemetry signal is detected.
US10/268,023 1998-02-27 2002-10-08 Rate adaptive cardiac rhythm management device using transthoracic impedance Abandoned US20030105499A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/268,023 US20030105499A1 (en) 1998-02-27 2002-10-08 Rate adaptive cardiac rhythm management device using transthoracic impedance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/032,731 US6076015A (en) 1998-02-27 1998-02-27 Rate adaptive cardiac rhythm management device using transthoracic impedance
US09/492,912 US6463326B1 (en) 1998-02-27 2000-01-20 Rate adaptive cardiac rhythm management device using transthoracic impedance
US10/268,023 US20030105499A1 (en) 1998-02-27 2002-10-08 Rate adaptive cardiac rhythm management device using transthoracic impedance

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/492,912 Continuation US6463326B1 (en) 1998-02-27 2000-01-20 Rate adaptive cardiac rhythm management device using transthoracic impedance

Publications (1)

Publication Number Publication Date
US20030105499A1 true US20030105499A1 (en) 2003-06-05

Family

ID=21866515

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/032,731 Expired - Lifetime US6076015A (en) 1998-02-27 1998-02-27 Rate adaptive cardiac rhythm management device using transthoracic impedance
US09/316,690 Expired - Lifetime US6161042A (en) 1998-02-27 1999-05-21 Rate adaptive cardiac rhythm management device using transthoracic impedance
US09/492,912 Expired - Lifetime US6463326B1 (en) 1998-02-27 2000-01-20 Rate adaptive cardiac rhythm management device using transthoracic impedance
US10/268,023 Abandoned US20030105499A1 (en) 1998-02-27 2002-10-08 Rate adaptive cardiac rhythm management device using transthoracic impedance

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/032,731 Expired - Lifetime US6076015A (en) 1998-02-27 1998-02-27 Rate adaptive cardiac rhythm management device using transthoracic impedance
US09/316,690 Expired - Lifetime US6161042A (en) 1998-02-27 1999-05-21 Rate adaptive cardiac rhythm management device using transthoracic impedance
US09/492,912 Expired - Lifetime US6463326B1 (en) 1998-02-27 2000-01-20 Rate adaptive cardiac rhythm management device using transthoracic impedance

Country Status (6)

Country Link
US (4) US6076015A (en)
EP (1) EP1061998B1 (en)
AT (1) ATE300332T1 (en)
CA (1) CA2322174A1 (en)
DE (1) DE69926347T2 (en)
WO (1) WO1999043385A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114889A1 (en) * 2000-07-14 2003-06-19 Cardiac Pacemakers, Inc. Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter
US20040049237A1 (en) * 2002-07-12 2004-03-11 Larson Dennis E. Minute ventilation sensor with dynamically adjusted excitation current
US20040102908A1 (en) * 2002-11-27 2004-05-27 Larson Dennis E. Minute ventilation sensor with automatic high pass filter adjustment
US20040186526A1 (en) * 2002-12-30 2004-09-23 Scott Freeberg Automatically configurable minute ventilation sensor
US20050004610A1 (en) * 2003-07-02 2005-01-06 Jaeho Kim Cardiac cycle synchronized sampling of impedance signal
US20060025661A1 (en) * 2004-08-02 2006-02-02 Sweeney Robert J Device for monitoring fluid status
US20060084881A1 (en) * 2004-10-20 2006-04-20 Lev Korzinov Monitoring physiological activity using partial state space reconstruction
US20060276848A1 (en) * 2005-06-06 2006-12-07 Xiaoyi Min Evoked response and impedance measures for monitoring heart failure and respiration
US7194306B1 (en) * 2003-09-05 2007-03-20 Pacesetter, Inc. Cardiac optimization through low-frequency analysis of hemodynamic variables
US20070096666A1 (en) * 2005-08-17 2007-05-03 Stryker Leibinger Gmbh & Co. Kg Surgical electrical tool, activation unit and calibration method therefor
US20070219453A1 (en) * 2006-03-14 2007-09-20 Michael Kremliovsky Automated analysis of a cardiac signal based on dynamical characteristics of the cardiac signal
US20090177110A1 (en) * 2008-01-08 2009-07-09 Cardiac Pacemakers, Inc Impedance measurement and demodulation using implantable device
US20100204599A1 (en) * 2009-02-10 2010-08-12 Cardionet, Inc. Locating fiducial points in a physiological signal
US20100305643A1 (en) * 2009-05-26 2010-12-02 Emerson Paul F Ventilation sensor rate response normalization and calculation
US20100327965A1 (en) * 2009-06-29 2010-12-30 Qualcomm Incorporated Receiver filtering devices, systems, and methods
US20110221590A1 (en) * 2010-03-15 2011-09-15 Welch Allyn, Inc. Personal Area Network Pairing
US8050764B2 (en) 2003-10-29 2011-11-01 Cardiac Pacemakers, Inc. Cross-checking of transthoracic impedance and acceleration signals
WO2012154706A1 (en) * 2011-05-09 2012-11-15 Medtronic, Inc. Techniques for modifying breathing date using cardiac pacing
US8907782B2 (en) 2010-06-30 2014-12-09 Welch Allyn, Inc. Medical devices with proximity detection
US8957777B2 (en) 2010-06-30 2015-02-17 Welch Allyn, Inc. Body area network pairing improvements for clinical workflows
TWI491250B (en) * 2013-03-15 2015-07-01 Quanta Comp Inc Modifying a digital video signal to mask biological information

Families Citing this family (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758503B2 (en) 1997-01-27 2010-07-20 Lynn Lawrence A Microprocessor system for the analysis of physiologic and financial datasets
US7081095B2 (en) * 2001-05-17 2006-07-25 Lynn Lawrence A Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US6609016B1 (en) 1997-07-14 2003-08-19 Lawrence A. Lynn Medical microprocessor system and method for providing a ventilation indexed oximetry value
US20050062609A9 (en) * 1992-08-19 2005-03-24 Lynn Lawrence A. Pulse oximetry relational alarm system for early recognition of instability and catastrophic occurrences
USD386557S (en) * 1996-06-10 1997-11-18 David Thompson Fishing rod holder
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US6022322A (en) 1998-02-06 2000-02-08 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6076015A (en) * 1998-02-27 2000-06-13 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device using transthoracic impedance
US7515896B1 (en) 1998-10-21 2009-04-07 Parkervision, Inc. Method and system for down-converting an electromagnetic signal, and transforms for same, and aperture relationships
US6061551A (en) 1998-10-21 2000-05-09 Parkervision, Inc. Method and system for down-converting electromagnetic signals
US6370371B1 (en) 1998-10-21 2002-04-09 Parkervision, Inc. Applications of universal frequency translation
US7295826B1 (en) * 1998-10-21 2007-11-13 Parkervision, Inc. Integrated frequency translation and selectivity with gain control functionality, and applications thereof
US7039372B1 (en) 1998-10-21 2006-05-02 Parkervision, Inc. Method and system for frequency up-conversion with modulation embodiments
US7236754B2 (en) 1999-08-23 2007-06-26 Parkervision, Inc. Method and system for frequency up-conversion
US6721600B2 (en) * 2000-01-19 2004-04-13 Medtronic, Inc. Implantable lead functional status monitor and method
US7209725B1 (en) 1999-01-22 2007-04-24 Parkervision, Inc Analog zero if FM decoder and embodiments thereof, such as the family radio service
US6317628B1 (en) 1999-01-25 2001-11-13 Cardiac Pacemakers, Inc. Cardiac rhythm management system with painless defribillation lead impedance measurement
US6853690B1 (en) 1999-04-16 2005-02-08 Parkervision, Inc. Method, system and apparatus for balanced frequency up-conversion of a baseband signal and 4-phase receiver and transceiver embodiments
US6879817B1 (en) 1999-04-16 2005-04-12 Parkervision, Inc. DC offset, re-radiation, and I/Q solutions using universal frequency translation technology
US7693230B2 (en) 1999-04-16 2010-04-06 Parkervision, Inc. Apparatus and method of differential IQ frequency up-conversion
US7110444B1 (en) 1999-08-04 2006-09-19 Parkervision, Inc. Wireless local area network (WLAN) using universal frequency translation technology including multi-phase embodiments and circuit implementations
US7065162B1 (en) 1999-04-16 2006-06-20 Parkervision, Inc. Method and system for down-converting an electromagnetic signal, and transforms for same
US8295406B1 (en) 1999-08-04 2012-10-23 Parkervision, Inc. Universal platform module for a plurality of communication protocols
US6535763B1 (en) * 1999-08-22 2003-03-18 Cardia Pacemakers, Inc. Event marker alignment by inclusion of event marker transmission latency in the real-time data stream
US6721594B2 (en) 1999-08-24 2004-04-13 Cardiac Pacemakers, Inc. Arrythmia display
US6963734B2 (en) * 1999-12-22 2005-11-08 Parkervision, Inc. Differential frequency down-conversion using techniques of universal frequency translation technology
US7010286B2 (en) 2000-04-14 2006-03-07 Parkervision, Inc. Apparatus, system, and method for down-converting and up-converting electromagnetic signals
IL163684A0 (en) * 2000-05-31 2005-12-18 Given Imaging Ltd Measurement of electrical characteristics of tissue
US7069070B2 (en) * 2003-05-12 2006-06-27 Cardiac Pacemakers, Inc. Statistical method for assessing autonomic balance
US7428436B2 (en) * 2000-11-02 2008-09-23 Cardiac Pacemakers, Inc. Method for exclusion of ectopic events from heart rate variability metrics
US7454453B2 (en) 2000-11-14 2008-11-18 Parkervision, Inc. Methods, systems, and computer program products for parallel correlation and applications thereof
US6665558B2 (en) 2000-12-15 2003-12-16 Cardiac Pacemakers, Inc. System and method for correlation of patient health information and implant device data
US6941167B2 (en) * 2000-12-15 2005-09-06 Cardiac Pacemakers, Inc. System and method for displaying cardiac events
US8548576B2 (en) 2000-12-15 2013-10-01 Cardiac Pacemakers, Inc. System and method for correlation of patient health information and implant device data
US7181285B2 (en) 2000-12-26 2007-02-20 Cardiac Pacemakers, Inc. Expert system and method
US7062641B1 (en) * 2001-01-10 2006-06-13 Cisco Technology, Inc. Method and apparatus for unified exception handling with distributed exception identification
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US6987998B2 (en) * 2001-02-28 2006-01-17 Cardiac Pacemakers, Inc. Cardiac rhythm management patient report
US7386344B2 (en) * 2004-08-11 2008-06-10 Cardiac Pacemakers, Inc. Pacer with combined defibrillator tailored for bradycardia patients
US6751502B2 (en) 2001-03-14 2004-06-15 Cardiac Pacemakers, Inc. Cardiac rhythm management system with defibrillation threshold prediction
US20050283197A1 (en) * 2001-04-10 2005-12-22 Daum Douglas R Systems and methods for hypotension
US6907288B2 (en) 2001-04-10 2005-06-14 Cardiac Pacemakers, Inc. Cardiac rhythm management system adjusting rate response factor for treating hypotension
US6912420B2 (en) 2001-04-10 2005-06-28 Cardiac Pacemakers, Inc. Cardiac rhythm management system for hypotension
US6684101B2 (en) 2001-04-25 2004-01-27 Cardiac Pacemakers, Inc. Implantable medical device employing single drive, dual sense impedance measuring
US6748271B2 (en) * 2001-07-27 2004-06-08 Cardiac Pacemakers, Inc. Method and system for treatment of neurocardiogenic syncope
US7191000B2 (en) * 2001-07-31 2007-03-13 Cardiac Pacemakers, Inc. Cardiac rhythm management system for edema
FR2829917B1 (en) * 2001-09-24 2004-06-11 Ela Medical Sa ACTIVE MEDICAL DEVICE INCLUDING MEANS FOR DIAGNOSING THE RESPIRATORY PROFILE
US7340303B2 (en) 2001-09-25 2008-03-04 Cardiac Pacemakers, Inc. Evoked response sensing for ischemia detection
US8359097B2 (en) * 2001-10-01 2013-01-22 Eckhard Alt Method of detecting sleep apnea and treatment thereof
US8781587B2 (en) * 2001-10-01 2014-07-15 Eckhard Alt Detecting and treatment of sleep apnea
US7383088B2 (en) * 2001-11-07 2008-06-03 Cardiac Pacemakers, Inc. Centralized management system for programmable medical devices
US7072427B2 (en) 2001-11-09 2006-07-04 Parkervision, Inc. Method and apparatus for reducing DC offsets in a communication system
US7085335B2 (en) * 2001-11-09 2006-08-01 Parkervision, Inc. Method and apparatus for reducing DC offsets in a communication system
US6728575B2 (en) * 2001-11-30 2004-04-27 St. Jude Medical Ab Method and circuit for detecting cardiac rhythm abnormalities using a differential signal from a lead with a multi-electrode tip
US7127289B2 (en) * 2001-12-05 2006-10-24 Cardiac Pacemakers, Inc. Cardiac resynchronization system employing mechanical measurement of cardiac walls
US6973349B2 (en) 2001-12-05 2005-12-06 Cardiac Pacemakers, Inc. Method and apparatus for minimizing post-infarct ventricular remodeling
US6963778B2 (en) * 2002-01-17 2005-11-08 Cardiac Pacemakers, Inc. Maximum pacing rate limiter implemented using the evoked response-T-wave interval
FR2834881B1 (en) * 2002-01-23 2004-10-22 Ela Medical Sa PHYSIOLOGICAL SIGNAL RECORDER, IN PARTICULAR HOLTER ECG SIGNAL RECORDER, INCLUDING MEANS OF DETECTION OF THE DISCONNECTION OR CUTTING OF THE LINK CABLES
US7983759B2 (en) 2002-12-18 2011-07-19 Cardiac Pacemakers, Inc. Advanced patient management for reporting multiple health-related parameters
US8391989B2 (en) 2002-12-18 2013-03-05 Cardiac Pacemakers, Inc. Advanced patient management for defining, identifying and using predetermined health-related events
US20040122294A1 (en) 2002-12-18 2004-06-24 John Hatlestad Advanced patient management with environmental data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US7043305B2 (en) 2002-03-06 2006-05-09 Cardiac Pacemakers, Inc. Method and apparatus for establishing context among events and optimizing implanted medical device performance
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US20040122487A1 (en) 2002-12-18 2004-06-24 John Hatlestad Advanced patient management with composite parameter indices
US6957105B2 (en) * 2002-03-26 2005-10-18 Cardiac Pacemakers, Inc. Method and apparatus for detecting oscillations in cardiac rhythm with electrogram signals
US7113825B2 (en) 2002-05-03 2006-09-26 Cardiac Pacemakers, Inc. Method and apparatus for detecting acoustic oscillations in cardiac rhythm
US7039462B2 (en) * 2002-06-14 2006-05-02 Cardiac Pacemakers, Inc. Method and apparatus for detecting oscillations in cardiac rhythm
WO2003092805A2 (en) 2002-05-03 2003-11-13 Cardiac Pacemakers, Inc. Method and apparatus for detecting oscillations in cardiac rhythm
US8417327B2 (en) * 2002-06-20 2013-04-09 Physio-Control, Inc. Variable frequency impedance measurement
US7142912B2 (en) * 2002-07-12 2006-11-28 Cardiac Pacemakers, Inc. Method and apparatus for assessing and treating atrial fibrillation risk
US7379883B2 (en) 2002-07-18 2008-05-27 Parkervision, Inc. Networking methods and systems
US7460584B2 (en) 2002-07-18 2008-12-02 Parkervision, Inc. Networking methods and systems
US6965797B2 (en) * 2002-09-13 2005-11-15 Cardiac Pacemakers, Inc. Method and apparatus for assessing and treating myocardial wall stress
US7226422B2 (en) * 2002-10-09 2007-06-05 Cardiac Pacemakers, Inc. Detection of congestion from monitoring patient response to a recumbent position
FR2846246B1 (en) * 2002-10-25 2005-06-24 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE OF CARDIAC STIMULATOR, DEFIBRILLATOR, CARDIOVERTOR, OR MULTISITE DEVICE WITH IMPROVED MANAGEMENT OF RESPIRATORY BREAKS OR HYPOPNEES
US7155280B2 (en) * 2002-11-01 2006-12-26 Cardiac Pacemakers, Inc. Rate-adaptive pacemaker with compensation for long-term variations in average exertion level
US7072711B2 (en) 2002-11-12 2006-07-04 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7016730B2 (en) * 2002-11-15 2006-03-21 Cardiac Pacemakers, Inc. Method of operating implantable medical devices to prolong battery life
US7313434B2 (en) * 2002-11-25 2007-12-25 Regents Of The University Of Minnesota Impedance monitoring for detecting pulmonary edema and thoracic congestion
US7189204B2 (en) 2002-12-04 2007-03-13 Cardiac Pacemakers, Inc. Sleep detection using an adjustable threshold
US7986994B2 (en) 2002-12-04 2011-07-26 Medtronic, Inc. Method and apparatus for detecting change in intrathoracic electrical impedance
US20050080348A1 (en) * 2003-09-18 2005-04-14 Stahmann Jeffrey E. Medical event logbook system and method
US7972275B2 (en) 2002-12-30 2011-07-05 Cardiac Pacemakers, Inc. Method and apparatus for monitoring of diastolic hemodynamics
US7378955B2 (en) * 2003-01-03 2008-05-27 Cardiac Pacemakers, Inc. System and method for correlating biometric trends with a related temporal event
US7136707B2 (en) 2003-01-21 2006-11-14 Cardiac Pacemakers, Inc. Recordable macros for pacemaker follow-up
US20040220636A1 (en) * 2003-04-29 2004-11-04 Medtronic, Inc. Cardiac pacing therapy parameter programming
US8414498B2 (en) * 2003-05-12 2013-04-09 Cheetah Medical, Inc. System, method and apparatus for measuring blood flow and blood volume
US7477932B2 (en) 2003-05-28 2009-01-13 Cardiac Pacemakers, Inc. Cardiac waveform template creation, maintenance and use
US7186220B2 (en) * 2003-07-02 2007-03-06 Cardiac Pacemakers, Inc. Implantable devices and methods using frequency-domain analysis of thoracic signal
US7050853B2 (en) * 2003-07-07 2006-05-23 Cardiac Pacemakers, Inc. Detection of patient mortality by an implantable medical device
US7396333B2 (en) 2003-08-18 2008-07-08 Cardiac Pacemakers, Inc. Prediction of disordered breathing
US7662101B2 (en) * 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US7757690B2 (en) 2003-09-18 2010-07-20 Cardiac Pacemakers, Inc. System and method for moderating a therapy delivered during sleep using physiologic data acquired during non-sleep
US7678061B2 (en) * 2003-09-18 2010-03-16 Cardiac Pacemakers, Inc. System and method for characterizing patient respiration
US7510531B2 (en) 2003-09-18 2009-03-31 Cardiac Pacemakers, Inc. System and method for discrimination of central and obstructive disordered breathing events
US8251061B2 (en) 2003-09-18 2012-08-28 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US7680537B2 (en) * 2003-08-18 2010-03-16 Cardiac Pacemakers, Inc. Therapy triggered by prediction of disordered breathing
US7967756B2 (en) * 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
US7720541B2 (en) * 2003-08-18 2010-05-18 Cardiac Pacemakers, Inc. Adaptive therapy for disordered breathing
US8002553B2 (en) 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US7668591B2 (en) * 2003-09-18 2010-02-23 Cardiac Pacemakers, Inc. Automatic activation of medical processes
US7572225B2 (en) * 2003-09-18 2009-08-11 Cardiac Pacemakers, Inc. Sleep logbook
US7468040B2 (en) * 2003-09-18 2008-12-23 Cardiac Pacemakers, Inc. Methods and systems for implantably monitoring external breathing therapy
US7336996B2 (en) * 2003-09-18 2008-02-26 Cardiac Pacemakers, Inc. Rate regularization of cardiac pacing for disordered breathing therapy
US7616988B2 (en) * 2003-09-18 2009-11-10 Cardiac Pacemakers, Inc. System and method for detecting an involuntary muscle movement disorder
US7469697B2 (en) * 2003-09-18 2008-12-30 Cardiac Pacemakers, Inc. Feedback system and method for sleep disordered breathing therapy
US8606356B2 (en) * 2003-09-18 2013-12-10 Cardiac Pacemakers, Inc. Autonomic arousal detection system and method
US8192376B2 (en) 2003-08-18 2012-06-05 Cardiac Pacemakers, Inc. Sleep state classification
EP1670547B1 (en) 2003-08-18 2008-11-12 Cardiac Pacemakers, Inc. Patient monitoring system
US7591265B2 (en) 2003-09-18 2009-09-22 Cardiac Pacemakers, Inc. Coordinated use of respiratory and cardiac therapies for sleep disordered breathing
US20050142070A1 (en) * 2003-09-18 2005-06-30 Hartley Jesse W. Methods and systems for assessing pulmonary disease with drug therapy control
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
US7392084B2 (en) 2003-09-23 2008-06-24 Cardiac Pacemakers, Inc. Demand-based cardiac function therapy
US7286872B2 (en) * 2003-10-07 2007-10-23 Cardiac Pacemakers, Inc. Method and apparatus for managing data from multiple sensing channels
US7572226B2 (en) 2003-10-28 2009-08-11 Cardiac Pacemakers, Inc. System and method for monitoring autonomic balance and physical activity
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7248923B2 (en) 2003-11-06 2007-07-24 Cardiac Pacemakers, Inc. Dual-use sensor for rate responsive pacing and heart sound monitoring
US7184821B2 (en) * 2003-12-03 2007-02-27 Regents Of The University Of Minnesota Monitoring thoracic fluid changes
US7319900B2 (en) 2003-12-11 2008-01-15 Cardiac Pacemakers, Inc. Cardiac response classification using multiple classification windows
US20060247693A1 (en) 2005-04-28 2006-11-02 Yanting Dong Non-captured intrinsic discrimination in cardiac pacing response classification
US8521284B2 (en) 2003-12-12 2013-08-27 Cardiac Pacemakers, Inc. Cardiac response classification using multisite sensing and pacing
US7774064B2 (en) 2003-12-12 2010-08-10 Cardiac Pacemakers, Inc. Cardiac response classification using retriggerable classification windows
US7471980B2 (en) * 2003-12-22 2008-12-30 Cardiac Pacemakers, Inc. Synchronizing continuous signals and discrete events for an implantable medical device
US7194307B2 (en) * 2003-12-22 2007-03-20 Cardiac Pacemakers, Inc. Pacing method and device for preserving native conduction system
US7389141B2 (en) * 2003-12-22 2008-06-17 Cardiac Pacemakers, Inc. Biatrial pacing optimization for biventricular pacing
US7123960B2 (en) 2003-12-22 2006-10-17 Cardiac Pacemakers, Inc. Method and system for delivering cardiac resynchronization therapy with variable atrio-ventricular delay
US7203540B2 (en) 2003-12-22 2007-04-10 Cardiac Pacemakers, Inc. Method and system for setting cardiac resynchronization therapy parameters
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US7460906B2 (en) 2003-12-24 2008-12-02 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US7706884B2 (en) 2003-12-24 2010-04-27 Cardiac Pacemakers, Inc. Baroreflex stimulation synchronized to circadian rhythm
US20050149132A1 (en) 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US7643875B2 (en) 2003-12-24 2010-01-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
US20050149129A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Baropacing and cardiac pacing to control output
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US7769450B2 (en) * 2004-11-18 2010-08-03 Cardiac Pacemakers, Inc. Cardiac rhythm management device with neural sensor
US8200331B2 (en) 2004-11-04 2012-06-12 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US9020595B2 (en) 2003-12-24 2015-04-28 Cardiac Pacemakers, Inc. Baroreflex activation therapy with conditional shut off
US7509166B2 (en) 2003-12-24 2009-03-24 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US8396560B2 (en) 2004-11-18 2013-03-12 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US7486991B2 (en) 2003-12-24 2009-02-03 Cardiac Pacemakers, Inc. Baroreflex modulation to gradually decrease blood pressure
US8025624B2 (en) 2004-02-19 2011-09-27 Cardiac Pacemakers, Inc. System and method for assessing cardiac performance through cardiac vibration monitoring
US7697990B2 (en) * 2004-02-20 2010-04-13 Resmed Limited Method and apparatus for detection and treatment of respiratory disorder by implantable device
US7299086B2 (en) 2004-03-05 2007-11-20 Cardiac Pacemakers, Inc. Wireless ECG in implantable devices
US7260431B2 (en) 2004-05-20 2007-08-21 Cardiac Pacemakers, Inc. Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device
US20050261596A1 (en) * 2004-05-24 2005-11-24 Smith Brian A Passive switched capacitor high-pass filter for implantable cardiac device
US7142920B2 (en) * 2004-05-25 2006-11-28 Cardiac Pacemakers, Inc. Chronotropic status monitor for implantable cardiac device
US7996083B2 (en) 2004-06-02 2011-08-09 Cardiac Pacemakers, Inc. Far-field sensing channel for implantable cardiac device
US20070191901A1 (en) * 2004-06-04 2007-08-16 Pacesetter, Inc. Quantifying systolic and diastolic cardiac performance from dynamic impedance waveforms
US7747323B2 (en) 2004-06-08 2010-06-29 Cardiac Pacemakers, Inc. Adaptive baroreflex stimulation therapy for disordered breathing
US7329226B1 (en) 2004-07-06 2008-02-12 Cardiac Pacemakers, Inc. System and method for assessing pulmonary performance through transthoracic impedance monitoring
US7751890B2 (en) * 2004-07-14 2010-07-06 Cardiac Pacemakers, Inc. Self-diagnostic method and system for implantable cardiac device
US7480528B2 (en) * 2004-07-23 2009-01-20 Cardiac Pacemakers, Inc. Method and apparatus for monitoring heart failure patients with cardiopulmonary comorbidities
US7559901B2 (en) * 2004-07-28 2009-07-14 Cardiac Pacemakers, Inc. Determining a patient's posture from mechanical vibrations of the heart
US7269458B2 (en) * 2004-08-09 2007-09-11 Cardiac Pacemakers, Inc. Cardiopulmonary functional status assessment via heart rate response detection by implantable cardiac device
US7389143B2 (en) * 2004-08-12 2008-06-17 Cardiac Pacemakers, Inc. Cardiopulmonary functional status assessment via metabolic response detection by implantable cardiac device
US7277756B2 (en) * 2004-08-16 2007-10-02 Cardiac Pacemakers, Inc. Risk of death indicator
US20060041279A1 (en) * 2004-08-18 2006-02-23 Yinghong Yu Detection and treatment of prolonged inter-atrial delay in cardiac resynchronization patients
US7387610B2 (en) 2004-08-19 2008-06-17 Cardiac Pacemakers, Inc. Thoracic impedance detection with blood resistivity compensation
US7647108B2 (en) * 2004-09-30 2010-01-12 Cardiac Pacemakers, Inc. Methods and systems for selection of cardiac pacing electrode configurations
US8175705B2 (en) * 2004-10-12 2012-05-08 Cardiac Pacemakers, Inc. System and method for sustained baroreflex stimulation
US8332047B2 (en) 2004-11-18 2012-12-11 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
JP2006185060A (en) * 2004-12-27 2006-07-13 Fujitsu Ltd Method for inputting password
US7295874B2 (en) * 2005-01-06 2007-11-13 Cardiac Pacemakers, Inc. Intermittent stress augmentation pacing for cardioprotective effect
US7662104B2 (en) 2005-01-18 2010-02-16 Cardiac Pacemakers, Inc. Method for correction of posture dependence on heart sounds
US7447543B2 (en) * 2005-02-15 2008-11-04 Regents Of The University Of Minnesota Pathology assessment with impedance measurements using convergent bioelectric lead fields
WO2006087696A2 (en) 2005-02-15 2006-08-24 Cheetah Medical Ltd. System, method and apparatus for measuring blood flow and blood volume
US7680534B2 (en) 2005-02-28 2010-03-16 Cardiac Pacemakers, Inc. Implantable cardiac device with dyspnea measurement
EP1863564B1 (en) 2005-03-11 2016-11-23 Cardiac Pacemakers, Inc. Combined neural stimulation and cardiac resynchronization therapy
US7587238B2 (en) 2005-03-11 2009-09-08 Cardiac Pacemakers, Inc. Combined neural stimulation and cardiac resynchronization therapy
US7660628B2 (en) 2005-03-23 2010-02-09 Cardiac Pacemakers, Inc. System to provide myocardial and neural stimulation
US7542800B2 (en) 2005-04-05 2009-06-02 Cardiac Pacemakers, Inc. Method and apparatus for synchronizing neural stimulation to cardiac cycles
US7630763B2 (en) * 2005-04-20 2009-12-08 Cardiac Pacemakers, Inc. Thoracic or intracardiac impedance detection with automatic vector selection
US8538519B2 (en) * 2005-04-25 2013-09-17 Cardiac Pacemakers, Inc. Method and system for treatment of mechanical cardiac asynchrony
US7603170B2 (en) * 2005-04-26 2009-10-13 Cardiac Pacemakers, Inc. Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance
US7392086B2 (en) 2005-04-26 2008-06-24 Cardiac Pacemakers, Inc. Implantable cardiac device and method for reduced phrenic nerve stimulation
US8781847B2 (en) 2005-05-03 2014-07-15 Cardiac Pacemakers, Inc. System and method for managing alert notifications in an automated patient management system
US7742813B2 (en) * 2005-05-06 2010-06-22 Cardiac Pacemakers, Inc. Minimizing hemodynamic compromise during post-mi remodeling control pacing
US7907997B2 (en) 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
US7340296B2 (en) 2005-05-18 2008-03-04 Cardiac Pacemakers, Inc. Detection of pleural effusion using transthoracic impedance
US7424321B2 (en) * 2005-05-24 2008-09-09 Cardiac Pacemakers, Inc. Systems and methods for multi-axis cardiac vibration measurements
US20060271121A1 (en) 2005-05-25 2006-11-30 Cardiac Pacemakers, Inc. Closed loop impedance-based cardiac resynchronization therapy systems, devices, and methods
US7922669B2 (en) 2005-06-08 2011-04-12 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US8620436B2 (en) 2005-07-08 2013-12-31 Boston Scientific Neuromodulation Corporation Current generation architecture for an implantable stimulator device having coarse and fine current control
US8606362B2 (en) 2005-07-08 2013-12-10 Boston Scientific Neuromodulation Corporation Current output architecture for an implantable stimulator device
US9839781B2 (en) 2005-08-22 2017-12-12 Cardiac Pacemakers, Inc. Intracardiac impedance and its applications
US8494618B2 (en) * 2005-08-22 2013-07-23 Cardiac Pacemakers, Inc. Intracardiac impedance and its applications
US7711425B2 (en) * 2005-08-22 2010-05-04 Cardiac Pacemakers, Inc. Defibrillation threshold prediction methods and systems
US7877140B2 (en) * 2005-09-06 2011-01-25 Cardiac Pacemakers, Inc. Pressure sensing for feedback control of post-MI remodeling control pacing
US20070055115A1 (en) * 2005-09-08 2007-03-08 Jonathan Kwok Characterization of sleep disorders using composite patient data
US8992436B2 (en) * 2005-09-16 2015-03-31 Cardiac Pacemakers, Inc. Respiration monitoring using respiration rate variability
US7974691B2 (en) * 2005-09-21 2011-07-05 Cardiac Pacemakers, Inc. Method and apparatus for controlling cardiac resynchronization therapy using cardiac impedance
US7917204B2 (en) * 2005-10-11 2011-03-29 St. Jude Medical Ab Method and implantable medical device for measuring an electrical bio-impedance of a patient
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8046060B2 (en) 2005-11-14 2011-10-25 Cardiac Pacemakers, Inc. Differentiating arrhythmic events having different origins
US20070118180A1 (en) 2005-11-18 2007-05-24 Quan Ni Cardiac resynchronization therapy for improved hemodynamics based on disordered breathing detection
US8108034B2 (en) 2005-11-28 2012-01-31 Cardiac Pacemakers, Inc. Systems and methods for valvular regurgitation detection
US7662105B2 (en) 2005-12-14 2010-02-16 Cardiac Pacemakers, Inc. Systems and methods for determining respiration metrics
US7920912B2 (en) * 2005-12-15 2011-04-05 Ivy Biomedical Systems, Inc. System and method for triggering a device based on an electrocardiogram signal
US8204585B2 (en) 2005-12-20 2012-06-19 Cardiac Pacemakers, Inc. Bio-impedance sensor and sensing method
US7826897B2 (en) * 2005-12-22 2010-11-02 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing rate monitoring
US7706852B2 (en) 2006-01-30 2010-04-27 Nellcor Puritan Bennett Llc System and method for detection of unstable oxygen saturation
US7937150B2 (en) * 2006-01-31 2011-05-03 Medtronic, Inc. Lead-carried proximal electrode for quadripolar transthoracic impedance monitoring
US7668579B2 (en) 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US20070208390A1 (en) * 2006-03-01 2007-09-06 Von Arx Jeffrey A Implantable wireless sound sensor
US7780606B2 (en) 2006-03-29 2010-08-24 Cardiac Pacemakers, Inc. Hemodynamic stability assessment based on heart sounds
US7744542B2 (en) * 2006-04-20 2010-06-29 Cardiac Pacemakers, Inc. Implanted air passage sensors
US7678058B2 (en) * 2006-06-22 2010-03-16 Cardiac Pacemakers, Inc. Apnea type determining apparatus and method
US8360983B2 (en) 2006-06-22 2013-01-29 Cardiac Pacemakers, Inc. Apnea type determining apparatus and method
US8000780B2 (en) 2006-06-27 2011-08-16 Cardiac Pacemakers, Inc. Detection of myocardial ischemia from the time sequence of implanted sensor measurements
US8226570B2 (en) 2006-08-08 2012-07-24 Cardiac Pacemakers, Inc. Respiration monitoring for heart failure using implantable device
US20080071185A1 (en) * 2006-08-08 2008-03-20 Cardiac Pacemakers, Inc. Periodic breathing during activity
US7680536B2 (en) * 2006-08-17 2010-03-16 Cardiac Pacemakers, Inc. Capture threshold estimation for alternate pacing vectors
US8343049B2 (en) * 2006-08-24 2013-01-01 Cardiac Pacemakers, Inc. Physiological response to posture change
US7818058B2 (en) * 2006-08-25 2010-10-19 Ivy Biomedical Systems, Inc. Automated ECG lead impedance measurement integrated into ECG gating circuitry
US8457734B2 (en) 2006-08-29 2013-06-04 Cardiac Pacemakers, Inc. System and method for neural stimulation
US7860567B2 (en) * 2006-08-31 2010-12-28 Cardiac Pacemakers, Inc. Sensor for edema
US8209013B2 (en) 2006-09-14 2012-06-26 Cardiac Pacemakers, Inc. Therapeutic electrical stimulation that avoids undesirable activation
US8948867B2 (en) * 2006-09-14 2015-02-03 Cardiac Pacemakers, Inc. Capture detection with cross chamber backup pacing
US7877139B2 (en) 2006-09-22 2011-01-25 Cameron Health, Inc. Method and device for implantable cardiac stimulus device lead impedance measurement
US7890163B2 (en) * 2006-10-19 2011-02-15 Cardiac Pacemakers, Inc. Method and apparatus for detecting fibrillation using cardiac local impedance
US8948868B2 (en) * 2006-10-31 2015-02-03 Medtronic, Inc. Methods and apparatus for manually suspending intrathoracic impedance fluid status measurements
US20080119749A1 (en) * 2006-11-20 2008-05-22 Cardiac Pacemakers, Inc. Respiration-synchronized heart sound trending
US8096954B2 (en) 2006-11-29 2012-01-17 Cardiac Pacemakers, Inc. Adaptive sampling of heart sounds
US8798749B2 (en) * 2006-12-14 2014-08-05 Cardiac Pacemakers, Inc. Cardiac stimulation device for sinus rate modulation
US8406879B2 (en) 2006-12-20 2013-03-26 Cardiac Pacemakers, Inc. Rate adaptive cardiac pacing systems and methods
US8033998B2 (en) * 2006-12-28 2011-10-11 Medtronic, Inc. Device and method for automatic threshold setting
US20080177156A1 (en) * 2007-01-19 2008-07-24 Cardiac Pacemakers, Inc. Ischemia detection using pressure sensor
US7736319B2 (en) 2007-01-19 2010-06-15 Cardiac Pacemakers, Inc. Ischemia detection using heart sound timing
US8014863B2 (en) * 2007-01-19 2011-09-06 Cardiac Pacemakers, Inc. Heart attack or ischemia detector
US9615744B2 (en) * 2007-01-31 2017-04-11 Medtronic, Inc. Chopper-stabilized instrumentation amplifier for impedance measurement
US7385443B1 (en) * 2007-01-31 2008-06-10 Medtronic, Inc. Chopper-stabilized instrumentation amplifier
US8265769B2 (en) * 2007-01-31 2012-09-11 Medtronic, Inc. Chopper-stabilized instrumentation amplifier for wireless telemetry
US7391257B1 (en) * 2007-01-31 2008-06-24 Medtronic, Inc. Chopper-stabilized instrumentation amplifier for impedance measurement
US8523771B2 (en) * 2007-02-12 2013-09-03 Cardiac Pacemakers, Inc. Cardiovascular pressure annotations and logbook
US8876725B2 (en) * 2007-02-23 2014-11-04 Cheetah Medical, Inc. Method and system for estimating exercise capacity
US9095271B2 (en) * 2007-08-13 2015-08-04 Cheetah Medical, Inc. Dynamically variable filter
US8764667B2 (en) * 2007-03-07 2014-07-01 Cheetah Medical, Inc. Method and system for monitoring sleep
US8052611B2 (en) 2007-03-14 2011-11-08 Cardiac Pacemakers, Inc. Method and apparatus for management of heart failure hospitalization
US7840267B2 (en) 2007-03-23 2010-11-23 Cardiac Pacemakers, Inc. Closed-loop resynchronization therapy for mechanical dyssynchrony
US7890167B2 (en) * 2007-04-03 2011-02-15 Cardiac Pacemakers, Inc. Pain free defibrillation threshold estimation
US7853327B2 (en) 2007-04-17 2010-12-14 Cardiac Pacemakers, Inc. Heart sound tracking system and method
ATE548967T1 (en) * 2007-04-19 2012-03-15 Cheetah Medical Inc METHOD AND APPARATUS FOR PREDICTING ELECTROCHEMICAL DISSOCIATION
US8781595B2 (en) * 2007-04-30 2014-07-15 Medtronic, Inc. Chopper mixer telemetry circuit
US8630704B2 (en) * 2007-06-25 2014-01-14 Cardiac Pacemakers, Inc. Neural stimulation with respiratory rhythm management
US8221323B2 (en) * 2007-08-03 2012-07-17 Cardiac Pacemakers, Inc. Using acoustic energy to compute a lung edema fluid status indication
US9037239B2 (en) 2007-08-07 2015-05-19 Cardiac Pacemakers, Inc. Method and apparatus to perform electrode combination selection
US8265736B2 (en) 2007-08-07 2012-09-11 Cardiac Pacemakers, Inc. Method and apparatus to perform electrode combination selection
US8380314B2 (en) 2007-09-26 2013-02-19 Medtronic, Inc. Patient directed therapy control
WO2009042172A2 (en) * 2007-09-26 2009-04-02 Medtronic, Inc. Frequency selective monitoring of physiological signals
US8417325B2 (en) * 2007-10-12 2013-04-09 Cardiac Pacemakers, Inc. Differentiating decompensation detection based on co-morbidities in heart failure
WO2009051638A1 (en) 2007-10-16 2009-04-23 Medtronic, Inc. Therapy control based on a patient movement state
US9078627B2 (en) 2008-01-04 2015-07-14 Texas Heart Institute Introducer sheath with electrodes
US8961417B2 (en) * 2008-01-04 2015-02-24 Texas Heart Institute Catheter with electrodes for impedance and/or conduction velocity measurement
WO2009094335A1 (en) * 2008-01-22 2009-07-30 Cardiac Pacemakers, Inc. Respiration as a trigger for therapy optimization
EP2249908B1 (en) 2008-01-25 2014-01-01 Medtronic, Inc. Sleep stage detection
US8548586B2 (en) * 2008-01-29 2013-10-01 Cardiac Pacemakers, Inc. Configurable intermittent pacing therapy
CN101939051B (en) 2008-02-14 2013-07-10 心脏起搏器公司 Method and apparatus for phrenic stimulation detection
US8275553B2 (en) 2008-02-19 2012-09-25 Nellcor Puritan Bennett Llc System and method for evaluating physiological parameter data
DE102008010651B4 (en) * 2008-02-22 2019-04-25 Biotronik Se & Co. Kg System and method for evaluating an impedance curve
WO2009117086A2 (en) * 2008-03-17 2009-09-24 Cardiac Pacemakers, Inc. Deactivation of intermittent pacing therapy
US8365730B2 (en) 2008-03-24 2013-02-05 Covidien Lp Method and system for classification of photo-plethysmographically detected respiratory effort
US20090247837A1 (en) * 2008-03-27 2009-10-01 Nellcor Puritan Bennett Llc System And Method For Diagnosing Sleep Apnea
US8255046B2 (en) * 2008-07-31 2012-08-28 Medtronic, Inc. Detecting worsening heart failure based on impedance measurements
US9713701B2 (en) 2008-07-31 2017-07-25 Medtronic, Inc. Using multiple diagnostic parameters for predicting heart failure events
US9849294B2 (en) * 2008-08-11 2017-12-26 Cardiac Pacemakers, Inc. Systems and methods for controlling rate responsive pacing
US8398555B2 (en) 2008-09-10 2013-03-19 Covidien Lp System and method for detecting ventilatory instability
US8202223B2 (en) * 2008-09-19 2012-06-19 Medtronic, Inc. Method and apparatus for determining respiratory effort in a medical device
US8319648B2 (en) * 2008-09-22 2012-11-27 Cardiac Pacemakers, Inc. System and method for detection of HF decompensation based on signs and symptoms
CN102176861B (en) 2008-10-10 2015-11-25 心脏起搏器公司 For the multi-sensor strategy of heart failure patient management
US8731653B2 (en) 2008-10-10 2014-05-20 Regents Of The University Of Minnesota Monitor of heart failure using bioimpedance
US8419645B2 (en) * 2008-10-16 2013-04-16 Biotronik Crm Patent Ag Respiration measurement by means of morphological operators
US8478402B2 (en) * 2008-10-31 2013-07-02 Medtronic, Inc. Determining intercardiac impedance
US20100113964A1 (en) * 2008-10-31 2010-05-06 Wahlstrand John D Determining intercardiac impedance
US8632473B2 (en) * 2009-01-30 2014-01-21 Medtronic, Inc. Detecting worsening heart failure based on fluid accumulation with respiratory confirmation
DE102009002399A1 (en) 2009-04-15 2010-10-21 Biotronik Crm Patent Ag Apparatus and method for processing physiological measurements
WO2010123679A1 (en) * 2009-04-22 2010-10-28 Cardiac Pacemakers, Inc. Dynamic selection of algorithms for arrhythmia detection
US8634915B2 (en) * 2009-05-27 2014-01-21 Cardiac Pacemakers, Inc. Activity sensor processing for phrenic nerve activation detection
US8626292B2 (en) * 2009-05-27 2014-01-07 Cardiac Pacemakers, Inc. Respiration sensor processing for phrenic nerve activation detection
US9149642B2 (en) * 2009-05-27 2015-10-06 Cardiac Pacemakers, Inc. Method and apparatus for phrenic nerve activation detection with respiration cross-checking
JP5410600B2 (en) 2009-05-27 2014-02-05 カーディアック ペースメイカーズ, インコーポレイテッド Detection of phrenic nerve activation
US20110009753A1 (en) 2009-07-10 2011-01-13 Yi Zhang Respiration Rate Trending for Detecting Early Onset of Worsening Heart Failure
US20110009760A1 (en) * 2009-07-10 2011-01-13 Yi Zhang Hospital Readmission Alert for Heart Failure Patients
US20110009746A1 (en) 2009-07-10 2011-01-13 Tran Binh C System and methods for pulmonary edema detection with implantable acoustic devices
US8031094B2 (en) * 2009-09-11 2011-10-04 Apple Inc. Touch controller with improved analog front end
US8457741B2 (en) 2009-10-22 2013-06-04 Cardiac Pacemakers, Inc. Estimation of dedicated bipolar pacing vector threshold
WO2011049878A1 (en) 2009-10-22 2011-04-28 Cardiac Pacemakers, Inc. Estimation of dedicated bipolar pacing vector threshold
US8271072B2 (en) * 2009-10-30 2012-09-18 Medtronic, Inc. Detecting worsening heart failure
US9770204B2 (en) 2009-11-11 2017-09-26 Medtronic, Inc. Deep brain stimulation for sleep and movement disorders
US20110130666A1 (en) * 2009-11-30 2011-06-02 Yanting Dong Enhanced reporting of pathological episodes
US10328267B2 (en) * 2010-02-15 2019-06-25 Cardiac Pacemakers, Inc. Methods for constructing posture calibration matrices
US8491491B2 (en) * 2010-03-02 2013-07-23 Data Sciences International, Inc. Respiration measurements and dosimetry control in inhalation testing systems
EP2407100A1 (en) * 2010-07-15 2012-01-18 Tanita Corporation Respiration characteristic analysis
EP2407102A1 (en) * 2010-07-15 2012-01-18 Tanita Corporation Respiration characteristic analysis apparatus and respiration characteristic analysis system
US10216893B2 (en) 2010-09-30 2019-02-26 Fitbit, Inc. Multimode sensor devices
US9132275B2 (en) 2010-11-18 2015-09-15 Cardiac Pacemakers, Inc. Automatic determination of chronotropic incompetence using atrial pacing at rest
AU2011344010B2 (en) 2010-12-15 2014-12-18 Cardiac Pacemakers, Inc. Posture detection using thoracic impedance
WO2012082692A2 (en) 2010-12-15 2012-06-21 Cardiac Pacemakers, Inc. Cardiac decompensation detection using multiple sensors
US10893824B2 (en) 2010-12-20 2021-01-19 Cardiac Pacemakers, Inc. Heart failure detection with a sequential classifier
US8858448B2 (en) 2010-12-20 2014-10-14 Cardiac Pacemakers, Inc. Monitoring projections along principal components of multiple sensors as an indicator of worsening heart failure
AU2011349755B2 (en) 2010-12-20 2015-01-22 Cardiac Pacemakers, Inc. Physiologic response to posture
US8639324B2 (en) * 2011-02-02 2014-01-28 Cardiac Pacemakers, Inc. Respiratory parameters for arrhythmia detection and therapy
US8467870B2 (en) * 2011-05-09 2013-06-18 Medtronic, Inc. Techniques for modifying breathing rate using cardiac pacing
ITMI20111177A1 (en) * 2011-06-28 2012-12-29 St Microelectronics Srl METHOD AND DEVICE FOR MEASURING THE ELECTRICAL IMPEDANCE OF BIOLOGICAL FABRICS
US8805511B2 (en) 2011-07-27 2014-08-12 Medtronic, Inc. Method and apparatus to detect subcerebral ischemia
US8706235B2 (en) 2011-07-27 2014-04-22 Medtronic, Inc. Transvenous method to induce respiration
US8478413B2 (en) 2011-07-27 2013-07-02 Medtronic, Inc. Bilateral phrenic nerve stimulation with reduced dyssynchrony
WO2013019494A2 (en) * 2011-08-02 2013-02-07 Valencell, Inc. Systems and methods for variable filter adjustment by heart rate metric feedback
US20130211855A1 (en) 2011-08-29 2013-08-15 LeAnne M. Eberle Algorithm for narrative generation
US8983611B2 (en) 2011-09-27 2015-03-17 Cardiac Pacemakers, Inc. Neural control of central sleep apnea
US8897879B2 (en) 2011-11-04 2014-11-25 Medtronic, Inc. Method and apparatus for therapies of the cardiovascular and cardiorenal system
US9295850B2 (en) * 2012-04-24 2016-03-29 Medtronic, Inc. Charge-balancing during electrical stimulation
US9044149B2 (en) 2012-06-22 2015-06-02 Fitbit, Inc. Heart rate data collection
US8948832B2 (en) 2012-06-22 2015-02-03 Fitbit, Inc. Wearable heart rate monitor
US9005129B2 (en) * 2012-06-22 2015-04-14 Fitbit, Inc. Wearable heart rate monitor
CN104718003B (en) 2012-07-25 2017-04-05 心脏起搏器股份公司 Electrode displacement is detected
US9039614B2 (en) 2013-01-15 2015-05-26 Fitbit, Inc. Methods, systems and devices for measuring fingertip heart rate
US10512407B2 (en) 2013-06-24 2019-12-24 Fitbit, Inc. Heart rate data collection
US9592327B2 (en) 2013-09-06 2017-03-14 Cardiac Pacemakers, Inc. Systems and methods for heart failure management
US9456763B2 (en) * 2013-09-11 2016-10-04 Medtronic, Inc. Apparatus and method for simultaneous capture of biopotential and tissue impedance signals
ES2537351B1 (en) 2013-11-04 2015-12-03 Universidad De Sevilla Intelligent bioimpedance sensor for biomedical applications
US9814409B2 (en) 2013-11-26 2017-11-14 Cardiac Pacemakers, Inc. Detection of chronic obstructive pulmonary disease exacerbations from breathing patterns
CN105814569B (en) 2013-12-06 2019-05-07 心脏起搏器股份公司 The drug of Chronic Obstructive Pulmonary Disease titrates and patient-monitoring
US9649496B2 (en) 2013-12-06 2017-05-16 Cardiac Pacemakers, Inc. Physiologic response to a therapy change using a ventricular filling characteristic
US9591986B2 (en) 2013-12-10 2017-03-14 Cardiac Pacemakers, Inc. Measuring atrial fibrillation burden using implantable device based sensors
EP3151727A1 (en) 2014-06-05 2017-04-12 Cardiac Pacemakers, Inc. The absolute thoracic impedance for heart failure risk stratification
US9924904B2 (en) 2014-09-02 2018-03-27 Medtronic, Inc. Power-efficient chopper amplifier
US10524734B2 (en) * 2014-10-08 2020-01-07 MAD Apparel, Inc. Method and system for measuring beat parameters
US9392946B1 (en) 2015-05-28 2016-07-19 Fitbit, Inc. Heart rate sensor with high-aspect-ratio photodetector element
WO2016196080A1 (en) 2015-06-02 2016-12-08 Cardiac Pacemakers, Inc. Multi-sensor volume index
US10166001B2 (en) 2015-10-27 2019-01-01 Cardiac Pacemakers, Inc. Trending S1 heart sounds amplitudes in ambulatory patients for worsening HF detection
WO2017095776A1 (en) * 2015-12-04 2017-06-08 Cardiac Pacemakers, Inc. Device-based sensor tracking for optimizing a cardiovascular medication administration protocol
US11206989B2 (en) 2015-12-10 2021-12-28 Fitbit, Inc. Light field management in an optical biological parameter sensor
US10568525B1 (en) 2015-12-14 2020-02-25 Fitbit, Inc. Multi-wavelength pulse oximetry
WO2017120558A1 (en) 2016-01-08 2017-07-13 Cardiac Pacemakers, Inc. Syncing multiple sources of physiological data
WO2017120560A1 (en) 2016-01-08 2017-07-13 Cardiac Pacemakers, Inc. Obtaining high-resolution information from an implantable medical device
WO2017120550A1 (en) 2016-01-08 2017-07-13 Cardiac Pacemakers, Inc. Progressive adaptive data transfer
WO2017139340A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Triggering storage of onset of physiologic condition
EP3422934B1 (en) 2016-03-04 2020-07-01 Cardiac Pacemakers, Inc. Reducing false positives in detection of potential cardiac pauses
US10850093B2 (en) 2016-04-13 2020-12-01 Cardiac Pacemakers, Inc. Lead integrity monitoring
US10631744B2 (en) 2016-04-13 2020-04-28 Cardiac Pacemakers, Inc. AF monitor and offline processing
EP3448249A4 (en) 2016-04-29 2019-10-09 Fitbit, Inc. Multi-channel photoplethysmography sensor
US10945670B2 (en) * 2016-07-06 2021-03-16 Cardiac Pacemakers, Inc. Minute volume sensor optimization using quadripolar leads
US10952686B2 (en) 2016-08-02 2021-03-23 Medtronic, Inc. Mobile application to prompt physical action to measure physiologic response in implantable device
US11051706B1 (en) 2017-04-07 2021-07-06 Fitbit, Inc. Multiple source-detector pair photoplethysmography (PPG) sensor
KR102049598B1 (en) * 2017-10-26 2019-11-27 계명대학교 산학협력단 Implantable impedance measurement devices and heart failure monitoring system using it
US11717186B2 (en) 2019-08-27 2023-08-08 Medtronic, Inc. Body stability measurement
US11602313B2 (en) 2020-07-28 2023-03-14 Medtronic, Inc. Determining a fall risk responsive to detecting body position movements
US20230068431A1 (en) 2021-08-13 2023-03-02 3Ive Labs, Llc Negative Pressure Therapy System and Methods
CN116458847A (en) * 2023-04-18 2023-07-21 中船海神医疗科技有限公司 Emergency equipment interference suppression method and system based on adaptive filtering

Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896817A (en) * 1971-08-06 1975-07-29 Arco Nuclear Co Implantable nerve stimulator
US4596251A (en) * 1984-02-07 1986-06-24 Gianni Plicchi Minute ventilation dependent rate responsive pacer
US4686987A (en) * 1981-06-18 1987-08-18 Cardiac Pacemakers, Inc. Biomedical method and apparatus for controlling the administration of therapy to a patient in response to changes in physiologic demand
US4702253A (en) * 1985-10-15 1987-10-27 Telectronics N.V. Metabolic-demand pacemaker and method of using the same to determine minute volume
US4722351A (en) * 1981-12-21 1988-02-02 American Home Products Corporation Systems and methods for processing physiological signals
US4781201A (en) * 1984-12-27 1988-11-01 American Home Products Corporation (Del.) Cardiovascular artifact filter
US4827935A (en) * 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US4830008A (en) * 1987-04-24 1989-05-16 Meer Jeffrey A Method and system for treatment of sleep apnea
US4858611A (en) * 1987-06-03 1989-08-22 Dimed, Inc. Sensing system and method for sensing minute ventilation
US4901725A (en) * 1988-01-29 1990-02-20 Telectronics N.V. Minute volume rate-responsive pacemaker
US4966146A (en) * 1988-01-14 1990-10-30 Webb Stuart C Rate-responsive pacemaker
US5027813A (en) * 1990-03-05 1991-07-02 Cardiac Pacemakers, Inc. Rate responsive pacemaker apparatus having an electrode interface sensor
US5063927A (en) * 1988-02-17 1991-11-12 Webb Stuart C Rate-responsive pacemaker
US5074303A (en) * 1990-03-08 1991-12-24 Cardiac Pacemakers, Inc. Rate adaptive cardiac pacer incorporating switched capacitor filter with cutoff frequency determined by heart rate
US5085215A (en) * 1990-03-20 1992-02-04 Telectronics Pacing Systems, Inc. Metabolic demand driven rate-responsive pacemaker
US5137019A (en) * 1990-03-08 1992-08-11 Cardiac Pacemakers, Inc. Variation in cardiac chamber volume or pressure as a controlling parameter
US5156147A (en) * 1991-02-05 1992-10-20 Cardiac Pacemakers, Inc. Variable rate pacemaker having upper rate limit governor based on hemodynamic performance
US5190035A (en) * 1981-06-18 1993-03-02 Cardiac Pacemakers, Inc. Biomedical method and apparatus for controlling the administration of therapy to a patient in response to changes in physiological demand
US5197467A (en) * 1992-06-22 1993-03-30 Telectronics Pacing Systems, Inc. Multiple parameter rate-responsive cardiac stimulation apparatus
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5201808A (en) * 1992-02-10 1993-04-13 Telectronics Pacing Systems, Inc. Minute volume rate-responsive pacemaker employing impedance sensing on a unipolar lead
US5235976A (en) * 1991-12-13 1993-08-17 Cardiac Pacemakers, Inc. Method and apparatus for managing and monitoring cardiac rhythm using active time as the controlling parameter
US5249572A (en) * 1990-12-27 1993-10-05 Ela Medical Method and apparatus for controlling the pacing rate of a metabolic demand pacemaker
US5271395A (en) * 1992-04-17 1993-12-21 Medtronic, Inc. Method and apparatus for rate-responsive cardiac pacing
US5273034A (en) * 1991-04-26 1993-12-28 Siemens Aktiengesellschaft Implantable medical apparatus for rate adaptive stimulation of a heart
US5284136A (en) * 1990-04-04 1994-02-08 Cardiac Pacemakers, Inc. Dual indifferent electrode pacemaker
US5300094A (en) * 1991-01-09 1994-04-05 Medtronic, Inc. Servo muscle control
US5303702A (en) * 1990-12-27 1994-04-19 Ela Medical Automatic adjustment of the control function for a rate adaptive pacemaker
US5318597A (en) * 1993-03-15 1994-06-07 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device control algorithm using trans-thoracic ventilation
US5379776A (en) * 1993-04-01 1995-01-10 Telectronics Pacing Systems, Inc. Heart rhythm classification method, and implantable dual chamber cardioverter/defibrillator employing the same
US5423870A (en) * 1993-11-22 1995-06-13 Cardiac Pacemakers, Inc. Rate responsive cardiac pacemaker
US5441524A (en) * 1993-08-30 1995-08-15 Medtronic, Inc. Energy efficient multiple sensor cardiac pacemaker
US5507785A (en) * 1994-12-21 1996-04-16 Intermedics, Inc. Rate responsive cardiac pacemaker with biphasic impedance sensing and method
US5524632A (en) * 1994-01-07 1996-06-11 Medtronic, Inc. Method for implanting electromyographic sensing electrodes
US5540733A (en) * 1994-09-21 1996-07-30 Medtronic, Inc. Method and apparatus for detecting and treating obstructive sleep apnea
US5562711A (en) * 1994-11-30 1996-10-08 Medtronic, Inc. Method and apparatus for rate-responsive cardiac pacing
US5562712A (en) * 1994-11-25 1996-10-08 Dow Corning Corporation Minute volume rate-responsive pacemaker using dual unipolar leads
US5626622A (en) * 1994-09-21 1997-05-06 Telectronics Pacing Systems, Inc. Dual sensor rate responsive pacemaker
US5792208A (en) * 1991-05-17 1998-08-11 Gray; Noel Domond Heart pacemaker
US5800470A (en) * 1994-01-07 1998-09-01 Medtronic, Inc. Respiratory muscle electromyographic rate responsive pacemaker
US5817135A (en) * 1997-05-02 1998-10-06 Pacesetter, Inc. Rate-responsive pacemaker with noise-rejecting minute volume determination
US5817136A (en) * 1997-05-02 1998-10-06 Pacesetter, Inc. Rate-responsive pacemaker with minute volume determination and EMI protection
US5824020A (en) * 1997-05-02 1998-10-20 Pacesetter, Inc. Rate-responsive pacemaker with rapid minute volume determination
US5824029A (en) * 1994-04-28 1998-10-20 Medtronic, Inc. Implantable medical system for performing transthoracic impedance measurements associated with cardiac function
US5836976A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Cardioversion energy reduction system
US5978707A (en) * 1997-04-30 1999-11-02 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6022322A (en) * 1998-02-06 2000-02-08 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6044294A (en) * 1995-12-15 2000-03-28 Pacesetter, Inc. Methods and apparatus for measuring impedance in the body
US6076015A (en) * 1998-02-27 2000-06-13 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device using transthoracic impedance
US6415183B1 (en) * 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
US20020123769A1 (en) * 2000-12-14 2002-09-05 Medtronic, Inc. Atrial aware VVI: a method for atrial synchronous ventricular (VDD/R) pacing using the subcutaneous electrode array and a standard pacing lead
US20020123768A1 (en) * 1999-08-20 2002-09-05 Cardiac Pacemakers, Inc. System and method for detection enhancement programming
US6459929B1 (en) * 1999-11-04 2002-10-01 Cardiac Pacemakers, Inc. Implantable cardiac rhythm management device for assessing status of CHF patients
US20030069609A1 (en) * 2001-10-09 2003-04-10 Medtronic, Inc. Method and apparatus for affecting atrial defibrillation with bi-atrial pacing
US20030114889A1 (en) * 2000-07-14 2003-06-19 Cardiac Pacemakers, Inc. Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter
US20040102908A1 (en) * 2002-11-27 2004-05-27 Larson Dennis E. Minute ventilation sensor with automatic high pass filter adjustment
US20040116820A1 (en) * 2002-12-13 2004-06-17 Daum Douglas R. Respiration signal measurement apparatus, systems, and methods
US20050004610A1 (en) * 2003-07-02 2005-01-06 Jaeho Kim Cardiac cycle synchronized sampling of impedance signal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2805482A1 (en) * 1978-02-09 1979-08-16 Hellige Gmbh FAIL-PROOF QRS DETECTOR WITH AUTOMATIC THRESHOLD
DE4231602B4 (en) * 1992-09-17 2004-11-04 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Circuit for measuring the impedance in the heart
US5540732A (en) * 1994-09-21 1996-07-30 Medtronic, Inc. Method and apparatus for impedance detecting and treating obstructive airway disorders
US5623938A (en) * 1995-09-29 1997-04-29 Siemens Medical Systems, Inc. Method and apparatus for respiration monitoring

Patent Citations (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896817A (en) * 1971-08-06 1975-07-29 Arco Nuclear Co Implantable nerve stimulator
US4686987A (en) * 1981-06-18 1987-08-18 Cardiac Pacemakers, Inc. Biomedical method and apparatus for controlling the administration of therapy to a patient in response to changes in physiologic demand
US5190035A (en) * 1981-06-18 1993-03-02 Cardiac Pacemakers, Inc. Biomedical method and apparatus for controlling the administration of therapy to a patient in response to changes in physiological demand
US4722351A (en) * 1981-12-21 1988-02-02 American Home Products Corporation Systems and methods for processing physiological signals
US4596251A (en) * 1984-02-07 1986-06-24 Gianni Plicchi Minute ventilation dependent rate responsive pacer
US4781201A (en) * 1984-12-27 1988-11-01 American Home Products Corporation (Del.) Cardiovascular artifact filter
US4702253A (en) * 1985-10-15 1987-10-27 Telectronics N.V. Metabolic-demand pacemaker and method of using the same to determine minute volume
US4827935A (en) * 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US4830008A (en) * 1987-04-24 1989-05-16 Meer Jeffrey A Method and system for treatment of sleep apnea
US4858611A (en) * 1987-06-03 1989-08-22 Dimed, Inc. Sensing system and method for sensing minute ventilation
US4966146A (en) * 1988-01-14 1990-10-30 Webb Stuart C Rate-responsive pacemaker
US4901725A (en) * 1988-01-29 1990-02-20 Telectronics N.V. Minute volume rate-responsive pacemaker
US5063927A (en) * 1988-02-17 1991-11-12 Webb Stuart C Rate-responsive pacemaker
US5027813A (en) * 1990-03-05 1991-07-02 Cardiac Pacemakers, Inc. Rate responsive pacemaker apparatus having an electrode interface sensor
US5074303A (en) * 1990-03-08 1991-12-24 Cardiac Pacemakers, Inc. Rate adaptive cardiac pacer incorporating switched capacitor filter with cutoff frequency determined by heart rate
US5137019A (en) * 1990-03-08 1992-08-11 Cardiac Pacemakers, Inc. Variation in cardiac chamber volume or pressure as a controlling parameter
US5391190A (en) * 1990-03-08 1995-02-21 Cardiac Pacemakers, Inc. Variation in cardiac chamber volume or pressure as a controlling parameter
US5085215A (en) * 1990-03-20 1992-02-04 Telectronics Pacing Systems, Inc. Metabolic demand driven rate-responsive pacemaker
US5284136A (en) * 1990-04-04 1994-02-08 Cardiac Pacemakers, Inc. Dual indifferent electrode pacemaker
US5249572A (en) * 1990-12-27 1993-10-05 Ela Medical Method and apparatus for controlling the pacing rate of a metabolic demand pacemaker
US5303702A (en) * 1990-12-27 1994-04-19 Ela Medical Automatic adjustment of the control function for a rate adaptive pacemaker
US5300094A (en) * 1991-01-09 1994-04-05 Medtronic, Inc. Servo muscle control
US5156147A (en) * 1991-02-05 1992-10-20 Cardiac Pacemakers, Inc. Variable rate pacemaker having upper rate limit governor based on hemodynamic performance
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5273034A (en) * 1991-04-26 1993-12-28 Siemens Aktiengesellschaft Implantable medical apparatus for rate adaptive stimulation of a heart
US5792208A (en) * 1991-05-17 1998-08-11 Gray; Noel Domond Heart pacemaker
US5235976A (en) * 1991-12-13 1993-08-17 Cardiac Pacemakers, Inc. Method and apparatus for managing and monitoring cardiac rhythm using active time as the controlling parameter
US5201808A (en) * 1992-02-10 1993-04-13 Telectronics Pacing Systems, Inc. Minute volume rate-responsive pacemaker employing impedance sensing on a unipolar lead
US5271395A (en) * 1992-04-17 1993-12-21 Medtronic, Inc. Method and apparatus for rate-responsive cardiac pacing
US5197467A (en) * 1992-06-22 1993-03-30 Telectronics Pacing Systems, Inc. Multiple parameter rate-responsive cardiac stimulation apparatus
US5318597A (en) * 1993-03-15 1994-06-07 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device control algorithm using trans-thoracic ventilation
US5379776A (en) * 1993-04-01 1995-01-10 Telectronics Pacing Systems, Inc. Heart rhythm classification method, and implantable dual chamber cardioverter/defibrillator employing the same
US5441524A (en) * 1993-08-30 1995-08-15 Medtronic, Inc. Energy efficient multiple sensor cardiac pacemaker
US5423870A (en) * 1993-11-22 1995-06-13 Cardiac Pacemakers, Inc. Rate responsive cardiac pacemaker
US5524632A (en) * 1994-01-07 1996-06-11 Medtronic, Inc. Method for implanting electromyographic sensing electrodes
US5800470A (en) * 1994-01-07 1998-09-01 Medtronic, Inc. Respiratory muscle electromyographic rate responsive pacemaker
US5824029A (en) * 1994-04-28 1998-10-20 Medtronic, Inc. Implantable medical system for performing transthoracic impedance measurements associated with cardiac function
US5540733A (en) * 1994-09-21 1996-07-30 Medtronic, Inc. Method and apparatus for detecting and treating obstructive sleep apnea
US5626622A (en) * 1994-09-21 1997-05-06 Telectronics Pacing Systems, Inc. Dual sensor rate responsive pacemaker
US5562712A (en) * 1994-11-25 1996-10-08 Dow Corning Corporation Minute volume rate-responsive pacemaker using dual unipolar leads
US5562711A (en) * 1994-11-30 1996-10-08 Medtronic, Inc. Method and apparatus for rate-responsive cardiac pacing
US5507785A (en) * 1994-12-21 1996-04-16 Intermedics, Inc. Rate responsive cardiac pacemaker with biphasic impedance sensing and method
US6044294A (en) * 1995-12-15 2000-03-28 Pacesetter, Inc. Methods and apparatus for measuring impedance in the body
US5836976A (en) * 1997-04-30 1998-11-17 Medtronic, Inc. Cardioversion energy reduction system
US5978707A (en) * 1997-04-30 1999-11-02 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US6151524A (en) * 1997-04-30 2000-11-21 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US20020107552A1 (en) * 1997-04-30 2002-08-08 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US6317632B1 (en) * 1997-04-30 2001-11-13 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US5817136A (en) * 1997-05-02 1998-10-06 Pacesetter, Inc. Rate-responsive pacemaker with minute volume determination and EMI protection
US5824020A (en) * 1997-05-02 1998-10-20 Pacesetter, Inc. Rate-responsive pacemaker with rapid minute volume determination
US5817135A (en) * 1997-05-02 1998-10-06 Pacesetter, Inc. Rate-responsive pacemaker with noise-rejecting minute volume determination
US6647289B2 (en) * 1998-02-06 2003-11-11 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6022322A (en) * 1998-02-06 2000-02-08 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6370424B1 (en) * 1998-02-06 2002-04-09 Intermedics Inc. Non-invasive cardiorespiratory monitor with synchronized bioimpedance sensing
US6076015A (en) * 1998-02-27 2000-06-13 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device using transthoracic impedance
US6161042A (en) * 1998-02-27 2000-12-12 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device using transthoracic impedance
US6463326B1 (en) * 1998-02-27 2002-10-08 Cardiac Pacemakers, Inc. Rate adaptive cardiac rhythm management device using transthoracic impedance
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US20020123768A1 (en) * 1999-08-20 2002-09-05 Cardiac Pacemakers, Inc. System and method for detection enhancement programming
US6459929B1 (en) * 1999-11-04 2002-10-01 Cardiac Pacemakers, Inc. Implantable cardiac rhythm management device for assessing status of CHF patients
US6415183B1 (en) * 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
US20030114889A1 (en) * 2000-07-14 2003-06-19 Cardiac Pacemakers, Inc. Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter
US20020123769A1 (en) * 2000-12-14 2002-09-05 Medtronic, Inc. Atrial aware VVI: a method for atrial synchronous ventricular (VDD/R) pacing using the subcutaneous electrode array and a standard pacing lead
US20030069609A1 (en) * 2001-10-09 2003-04-10 Medtronic, Inc. Method and apparatus for affecting atrial defibrillation with bi-atrial pacing
US20040102908A1 (en) * 2002-11-27 2004-05-27 Larson Dennis E. Minute ventilation sensor with automatic high pass filter adjustment
US20040116820A1 (en) * 2002-12-13 2004-06-17 Daum Douglas R. Respiration signal measurement apparatus, systems, and methods
US20050004610A1 (en) * 2003-07-02 2005-01-06 Jaeho Kim Cardiac cycle synchronized sampling of impedance signal

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7062326B2 (en) 2000-07-14 2006-06-13 Cardiac Pacemakers, Inc. Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter
US20030114889A1 (en) * 2000-07-14 2003-06-19 Cardiac Pacemakers, Inc. Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter
US20040049237A1 (en) * 2002-07-12 2004-03-11 Larson Dennis E. Minute ventilation sensor with dynamically adjusted excitation current
US7092757B2 (en) 2002-07-12 2006-08-15 Cardiac Pacemakers, Inc. Minute ventilation sensor with dynamically adjusted excitation current
US20040102908A1 (en) * 2002-11-27 2004-05-27 Larson Dennis E. Minute ventilation sensor with automatic high pass filter adjustment
US6868346B2 (en) * 2002-11-27 2005-03-15 Cardiac Pacemakers, Inc. Minute ventilation sensor with automatic high pass filter adjustment
US7272442B2 (en) 2002-12-30 2007-09-18 Cardiac Pacemakers, Inc. Automatically configurable minute ventilation sensor
US8423142B2 (en) 2002-12-30 2013-04-16 Cardiac Pacemakers, Inc. Cross-checking of transthoracic impedance and acceleration signals
US8209011B2 (en) 2002-12-30 2012-06-26 Cardiac Pacemakers, Inc. Automatically configurable minute ventilation sensor
US20040186526A1 (en) * 2002-12-30 2004-09-23 Scott Freeberg Automatically configurable minute ventilation sensor
US7200440B2 (en) 2003-07-02 2007-04-03 Cardiac Pacemakers, Inc. Cardiac cycle synchronized sampling of impedance signal
US8442633B2 (en) 2003-07-02 2013-05-14 Cardiac Pacemakers, Inc. Cardiac cycle synchronized sampling of impedance signal
US8880171B2 (en) 2003-07-02 2014-11-04 Cardiac Pacemakers, Inc. Cardiac cycle synchronized sampling of impedance signal
US8688214B2 (en) 2003-07-02 2014-04-01 Cardiac Pacemakers. Inc. Cardiac cycle synchronized sampling of impedance signal
US20050004610A1 (en) * 2003-07-02 2005-01-06 Jaeho Kim Cardiac cycle synchronized sampling of impedance signal
US8306621B2 (en) 2003-07-02 2012-11-06 Cardiac Pacemakers, Inc. Cardiac cycle synchronized sampling of impedance signal
US7194306B1 (en) * 2003-09-05 2007-03-20 Pacesetter, Inc. Cardiac optimization through low-frequency analysis of hemodynamic variables
US8050764B2 (en) 2003-10-29 2011-11-01 Cardiac Pacemakers, Inc. Cross-checking of transthoracic impedance and acceleration signals
US7356366B2 (en) 2004-08-02 2008-04-08 Cardiac Pacemakers, Inc. Device for monitoring fluid status
US20080188730A1 (en) * 2004-08-02 2008-08-07 Cardiac Pacemakers, Inc. Device for monitoring fluid status
US20060025661A1 (en) * 2004-08-02 2006-02-02 Sweeney Robert J Device for monitoring fluid status
US8103326B2 (en) 2004-08-02 2012-01-24 Cardiac Pacemakers, Inc. Device for monitoring fluid status
US7996075B2 (en) 2004-10-20 2011-08-09 Cardionet, Inc. Monitoring physiological activity using partial state space reconstruction
US20060084881A1 (en) * 2004-10-20 2006-04-20 Lev Korzinov Monitoring physiological activity using partial state space reconstruction
US20060276848A1 (en) * 2005-06-06 2006-12-07 Xiaoyi Min Evoked response and impedance measures for monitoring heart failure and respiration
EP1731088A1 (en) * 2005-06-06 2006-12-13 Pacesetter, Inc. Implantable cardiac diagnostic system
US7430447B2 (en) 2005-06-06 2008-09-30 Pacesetter, Inc. Evoked response and impedance measures for monitoring heart failure and respiration
US20070096666A1 (en) * 2005-08-17 2007-05-03 Stryker Leibinger Gmbh & Co. Kg Surgical electrical tool, activation unit and calibration method therefor
US8866419B2 (en) * 2005-08-17 2014-10-21 Stryker Leibinger Gmbh & Co. Kg Surgical electrical tool, activation unit and calibration method therefor
US7729753B2 (en) 2006-03-14 2010-06-01 Cardionet, Inc. Automated analysis of a cardiac signal based on dynamical characteristics of the cardiac signal
US20070219453A1 (en) * 2006-03-14 2007-09-20 Michael Kremliovsky Automated analysis of a cardiac signal based on dynamical characteristics of the cardiac signal
US9357944B2 (en) 2008-01-08 2016-06-07 Cardiac Pacemakers, Inc. Impedance measurement and demodulation using implantable device
US20090177110A1 (en) * 2008-01-08 2009-07-09 Cardiac Pacemakers, Inc Impedance measurement and demodulation using implantable device
US8200319B2 (en) 2009-02-10 2012-06-12 Cardionet, Inc. Locating fiducial points in a physiological signal
US20100204599A1 (en) * 2009-02-10 2010-08-12 Cardionet, Inc. Locating fiducial points in a physiological signal
US20100305643A1 (en) * 2009-05-26 2010-12-02 Emerson Paul F Ventilation sensor rate response normalization and calculation
US8914107B2 (en) 2009-05-26 2014-12-16 Cardiac Pacemakers, Inc. Ventilation sensor rate response normalization and calculation
US8781430B2 (en) * 2009-06-29 2014-07-15 Qualcomm Incorporated Receiver filtering devices, systems, and methods
US20100327965A1 (en) * 2009-06-29 2010-12-30 Qualcomm Incorporated Receiver filtering devices, systems, and methods
US9973883B2 (en) 2010-03-15 2018-05-15 Welch Allyn, Inc. Personal area network pairing
US9662016B2 (en) 2010-03-15 2017-05-30 Welch Allyn, Inc. Personal area network pairing
US20110221590A1 (en) * 2010-03-15 2011-09-15 Welch Allyn, Inc. Personal Area Network Pairing
US9504388B2 (en) 2010-03-15 2016-11-29 Welch Allyn, Inc. Personal area network pairing
US9000914B2 (en) * 2010-03-15 2015-04-07 Welch Allyn, Inc. Personal area network pairing
US9402545B2 (en) 2010-06-30 2016-08-02 Welch Allyn, Inc. Medical devices with proximity detection
US9386924B2 (en) 2010-06-30 2016-07-12 Welch Allyn, Inc. Body area network pairing improvements for clinical workflows
US8957777B2 (en) 2010-06-30 2015-02-17 Welch Allyn, Inc. Body area network pairing improvements for clinical workflows
US8907782B2 (en) 2010-06-30 2014-12-09 Welch Allyn, Inc. Medical devices with proximity detection
US10136817B2 (en) 2010-06-30 2018-11-27 Welch Allyn, Inc. Body area network pairing improvements for clinical workflows
US8483833B2 (en) 2011-05-09 2013-07-09 Medtronic, Inc. Techniques for modifying breathing rate using cardiac pacing
WO2012154706A1 (en) * 2011-05-09 2012-11-15 Medtronic, Inc. Techniques for modifying breathing date using cardiac pacing
TWI491250B (en) * 2013-03-15 2015-07-01 Quanta Comp Inc Modifying a digital video signal to mask biological information

Also Published As

Publication number Publication date
WO1999043385A1 (en) 1999-09-02
EP1061998B1 (en) 2005-07-27
US6161042A (en) 2000-12-12
DE69926347D1 (en) 2005-09-01
DE69926347T2 (en) 2006-05-24
ATE300332T1 (en) 2005-08-15
US6076015A (en) 2000-06-13
US6463326B1 (en) 2002-10-08
EP1061998A1 (en) 2000-12-27
CA2322174A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
US6463326B1 (en) Rate adaptive cardiac rhythm management device using transthoracic impedance
US8209011B2 (en) Automatically configurable minute ventilation sensor
US7092757B2 (en) Minute ventilation sensor with dynamically adjusted excitation current
US6868346B2 (en) Minute ventilation sensor with automatic high pass filter adjustment
US5318597A (en) Rate adaptive cardiac rhythm management device control algorithm using trans-thoracic ventilation
JP2551696B2 (en) Rate-adaptive pacer using breathing-related changes in ventricular volume or pressure as control parameters
US6449509B1 (en) Implantable stimulation device having synchronous sampling for a respiration sensor
US8688214B2 (en) Cardiac cycle synchronized sampling of impedance signal
US4919136A (en) Ventilation controlled rate responsive cardiac pacemaker
US9357944B2 (en) Impedance measurement and demodulation using implantable device
US7155275B2 (en) Method and apparatus for adjusting cardiac event detection threshold based on dynamic noise estimation
JP2708420B2 (en) Cardiac pacemaker
WO2001028625A1 (en) Apparatus and methods for mets measurement by accelerometer and minute ventilation sensors
US8914107B2 (en) Ventilation sensor rate response normalization and calculation
US10918869B2 (en) Methods and systems that monitor and respond to changes in physiological status based on measurements of respiration characteristics and pulmonary arterial pressure obtained from implantable sensors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION